Melanocortin receptor ligands

专利摘要:
The present invention discloses an MC-3 / MC-4 receptor ligand of Formula I: [Wherein A is a) a non-aromatic carbocyclic ring; b) aromatic carbocyclic rings; c) non-aromatic heterocyclic rings; d) a steric structurally restricted ring system selected from the group consisting of aromatic heterocyclic rings; Wherein said rings contain 5 to 8 atoms; W is preferably a unit containing D-1-fluorophenylalanine, Y contains a heteroatom, and Z contains an aromatic carbocyclic ring. The present invention also discloses pharmaceutical compositions containing the ligands of the invention and methods of treating diseases mediated through the MC-3 / MC-4 receptor.
公开号:KR20040007509A
申请号:KR10-2003-7013997
申请日:2002-04-24
公开日:2004-01-24
发明作者:마주르애덤위즐로；톈신롱；후슈펑에릭；에베티노프랭크홀락
申请人:더 프록터 앤드 갬블 캄파니；
IPC主号:

专利说明:

Melanocortin Receptor Ligand {MELANOCORTIN RECEPTOR LIGANDS}
[2] Melanocortin peptide (melanocortin) is a natural peptide hormone in animals and humans that binds to and stimulates the MC receptor. Examples of melanocortin include α-MSH (melanin cell stimulating hormone), β-MHS, γ-MSH, ACTH (adrenal cortical stimulating hormone) and their peptide fragments. MSH is primarily known for its ability to control peripheral pigmentation, while ACTH is known to induce steroidoneogenesis. Melanocortin peptides also mediate many other physiological actions. These include synchronization, learning, memory, behavior, inflammation, body temperature, pain perception, blood pressure, heart rate, vascular tone, natriuresis, cerebrovascular flow, nerve growth and recovery, placental development, aldosterone synthesis and release, thyroxine Effects on release, spermatogenesis, ovarian weight, prolactin and FSH secretion, uterine bleeding, sebum and pheromone secretion, sexual activity, erection, blood sugar levels, intrauterine fetal growth, food synchronized behavior, and other cases related to delivery It is reported to have.
[3] Both MC-4 and MC-3 receptors are located in the hypothalamus, an area of the brain thought to be involved in the regulation of dietary behavior. Compounds that show selectivity for the MC-3 / MC-4 receptor have been shown to alter food intake after endothelial and peripheral injection in rodents. Specifically, agonists have been shown to reduce diet, while antagonists have been shown to increase diet. The role of MC-4 and MC-3 receptors has been defined to control weight control in mammals. MC-3 receptors are thought to affect dietary efficiency and distribution of fuel storage to fats, while MC-4 receptors are thought to regulate food intake and possibly energy consumption. Thus, these receptor subtypes appear to lose weight through different and complementary pathways. Thus, compounds that stimulate both MC-3 and MC-4 receptors will have a greater weight loss effect than those selective for either MC-3 or MC-4 receptors.
[4] Weight disorders such as obesity, anorexia and cachexia are widely recognized as important public health problems and there is a need for compounds and pharmaceutical compositions that can treat these disorders.
[5] Applicants have surprisingly high affinity for the MC-4 and / or MC-3 receptor subtypes and are typically selective for these MC receptors over other melanocortin receptor subtypes, particularly the MC-1 subtype. A group of compounds was found.
[1] The present invention is directed to melanocortin (MC) receptor ligands that provide enhanced action with conformationally restricted ring components. These ligands preferably exhibit selectivity for MC-3 and / or MC-4 receptors over other melanocortin receptors (particularly MC-1 receptors) and are suitable for use in pharmaceutical compositions and therapeutic methods.
[6] Summary of the Invention
[7] The present invention relates to a group of compounds which are ligands for MC-3 and / or MC-4 receptors and contain 5-8 membered rings which stericly restrict the orientation of the three pendant units.
[8] Compounds of the present invention include both enantiomeric and diastereomeric forms and pharmaceutically acceptable salts thereof, wherein the compounds have the formula:
[9] (I).
[10] Where A is
[11] a) non-aromatic carbocyclic ring;
[12] b) aromatic carbocyclic rings;
[13] c) non-aromatic heterocyclic rings;
[14] d) aromatic heterocyclic rings;
[15] A stereoscopically restricted ring system selected from the group consisting of; The ring contains 5 to 8 atoms;
[16] W is a pendant unit having the formula:
[17]
[18] [Wherein R is
[19] a) non-aromatic carbocyclic ring;
[20] b) aromatic carbocyclic rings;
[21] c) non-aromatic heterocyclic rings;
[22] d) aromatic heterocyclic rings;
[23] It is selected from the group consisting of; The ring contains 3 to 12 atoms;
[24] J is selected from the group consisting of:
[25] i) - [C (R - ; and ") _{d] k} wherein each R" is independently hydrogen, C ₁ ~ C ₁₂ straight or branched alkyl, -SUB, two R "units carboxylic together with the oxygen atoms A carbonyl or heterocyclic fused ring, bicyclic, which may form a carbonyl unit, wherein two R "units from any J unit or R" units and R 'units from any T unit together contain 3 to 7 atoms A ring, or a spiroannulated ring, may form an index d having a value of 1 or 2, and an index k having a value of 1 or 2;
[26] ii) ;
[27] iii) -NR'-; R 'is hydrogen, C ₁ -C ₆ linear or branched alkyl or SUB unit;
[28] iv) -O-;
[29] v) -S-;
[30] vi) -P (O)-or -P (O) _2- ;
[31] vii) and mixtures thereof;
[32] L is a suitable linking unit;
[33] B is
[34] a) hydrogen;
[35] b) substituted or unsubstituted aromatic carbocyclic rings;
[36] c) substituted or unsubstituted aromatic heterocyclic ring; And
[37] d) contains units selected from the group consisting of mixtures thereof.]
[38] Y is a pendant unit containing one or more heteroatoms;
[39] Z is a pendant unit, which contains an aromatic or non-aromatic ring moiety.
[40] The present invention also relates to pharmaceutical compositions containing the MC and / or MC4 receptor ligands described herein, wherein the ligand has high affinity and selectivity for the MC3 receptor and / or MC4 receptor subtypes.
[41] These and other objects, features, and advantages will be apparent to those skilled in the art from the following detailed description and the contents of the appended claims. All percentages, ratios, ratios herein are by weight unless otherwise specified. All temperatures are in degrees Celsius (° C.) unless otherwise specified. All references mentioned are hereby incorporated by reference in their entirety.
[42] Detailed description of the invention
[43] The present invention relates to receptor ligands. Melacortin (MC) family of peptides mediate a wide range of physiological actions. Synthetic peptides and peptide analogs that regulate the interaction of native MC ligands have varying degrees of selectivity and degree of binding. The present invention relates to ligands that are selective for the MC4 receptor or selective for both the MC4 and MC3 receptors while minimizing the interaction at the MC1, MC2 and MC5 receptors.
[44] Surprisingly, it has been found that the conformational restriction of rotation along key peptide linkages provides receptor ligands with increased selectivity and binding. The technical clue of the present invention is that the conformationally constrained structure may in some embodiments contain five- and six-membered rings and chemical bonds that simply limit the rotation of structural isosteres, in particular normal peptide linkages. I could find that.
[45] While not wishing to be bound by theory, once the peptide or peptide analog rotation is fixed, the suspended portions of the results begin to differentiate with themselves, which is involved in their physiological and biological functions. Suspension units or portions from the core ring structure are referred to herein as "W pendant units" or "units", "Y pendant units" or "units with base portions, quaternary nitrogen portions, or mixtures thereof"; And "Z pendant units". The units are thus named as a memory device (mnemonic) that assists the formulator in conceptualizing the categories and embodiments described herein as well as assisting in the differentiation of their predicted functionality. Thus, units conveniently described as units (W pendant units) may play one or more other roles in eliciting desirable physiological and biological responses. The scope of the present invention is not limited by this need to differentiate the appendages merely to clearly define the boundaries and is not bound to each group, unit or part.
[46] With respect to the term “amino acid,” those skilled in the art will recognize that the term refers to naturally occurring constituents and non-naturally occurring variants of peptides, enzymes and the like. The following is a general list of common amino acids in their abbreviation and one letter code: alanine (Ala, A); Arginine (Arg; R); Asparagine (Asp, N); Aspartic acid (Asp, D), cysteine (Cys, C); Glutamic acid (Glu, Q); Glutamine (Gln, E); Glycine (Gly, G); Histidine (His, H); Isoleucine (Ile, I); Leucine (Leu, L); Lysine (Lys, K); Methionine (Met, M); Phenylalanine (Phe, F); Proline (Pro, P); Serine (Ser, S); Threonine (Thr, T), tryptophan (Trp, W); Tyrosine (Tyr, Y); Valine (Val, V). Other non-naturally occurring amino acids include p-benzoyl-phenylalanine (Bpa); β- (1-naphthyl) -alanine (1-Nal); β- (2-naphthyl) -alanine (2-Nal); β-cyclohexylalanine (Cha), 3,4-dichlorophenylalanine (3,4-Dcp); 4-fluorophenylalanine (4-Fpa); 4-nitrophenylalanine (4-Npa); 2-thienylalanine (Tha); 1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid (Tic); 3-benzothienylalanine (3-Bal); 4-cyanophenylalanine (4-Ypa); 4-iodophenylalanine (4-lpa); 4-bromophenylalanine (4-Rpa); 4,4'-biphenylalanine (Bip); Ornithine (Orn); Sarcosine (Sar); Pentafluorophenylalanine (Pfp); And β, β-diphenylalanine (Dip). For the purposes of the present invention, unless otherwise indicated, the amino acids are L-type (left-handed). In general amino acids, the D-type is abbreviated as follows, for example, D-alanine is represented by "a" and D-threonine is represented by "t".
[47] For the purposes of the present invention, in describing particular embodiments or embodiments, one or more units will be indicated or highlighted by an asterisk, eg R ^* , J ^* . This is provided to clearly show only one unit and the other, and to emphasize that the embodiment is focused on change or repetition in a specific unit. By way of example, each J unit may contain the same component regardless of whether J or J ^* , but in certain embodiments the emphasis is on the value of the J unit.
[48] Substitution unit, -SUB
[49] SUB is a unit that can replace a hydrogen atom. The term "substituted" is used throughout the specification, and the term "substituted" for the purposes of the present invention refers to "one hydrogen atom, two hydrogen atoms, or three hydrogen atoms from a carbon atom. Alternatively forming a portion or replacing hydrogen atoms from adjacent carbon atoms to form a portion ". By way of example, the substitution units required for replacing a single hydrogen atom include halogen, hydroxyl, and the like. Two hydrogen atom substitutions include carbonyl, oxymino, and the like. Three hydrogen replacements include cyano and the like. The expression substitution is used throughout this specification to indicate that some portions, particularly aromatic rings, alkyl chains, may have one or more hydrogen atoms replaced by substituents. By way of example, 4-hydroxyphenyl is a "substituted aromatic carbocyclic ring" and 3-guanidinopropyl is a "substituted C ₃ alkyl unit". The expression -SUB 'is used to denote units in which the substituent on hydrogen is hydrogen bondable, in particular hydroxyl, carbonyl.
[50] The following are non-limiting examples of moieties that can replace one or more hydrogen atoms on a carbon atom to form a -SUB unit:
[51]
[52]
[53] Wherein R ³⁰ is hydrogen, C ₁ -C ₂₀ linear or branched alkyl, C ₆ -C ₂₀ aryl, C ₇ -C ₂₀ alkylenearyl, and mixtures thereof; M is hydrogen or a salt forming cation. Suitable salt forming cations include sodium, lithium, potassium, calcium, magnesium, ammonium and the like. Non-limiting examples of alkylenearyl units include benzyl, 2-phenylethyl, 3-phenylpropyl, and 2-phenylpropyl. As further described herein below, the units defined herein as "hydrogen bond-formable substitution units" include -SUB 'units, examples of which include hydroxyl and carbonyl.
[54] For illustrative purposes, the following is a conformationally restricted ring having W, Y, and Z units and SUB substituted units attached thereto. In this example, -SUB is acetate (group (ii), wherein R ³⁰ is methyl):
[55]
[56] For the purposes of the present invention, the substitution for one hydrogen atom can occur on the hydrocarbyl backbone or on the branched chain.
[57] The conformationally limited ligands of the present invention include all enantiomeric and diastereoisomeric forms and pharmaceutically acceptable salts thereof, as described below, wherein the ligands have the formula:
[58]
[59] Where A is
[60] a) non-aromatic carbocyclic ring;
[61] b) aromatic carbocyclic rings;
[62] c) non-aromatic heterocyclic rings;
[63] d) a conformationally restricted ring system selected from the group consisting of aromatic heterocyclic rings; Wherein the rings contain 5 to 8 atoms. The formulator may select any of these four types of ring systems. For the purposes of the present invention, the expression "carbocyclic ring" is defined herein as "any ring containing only carbon atoms". The carbon atoms may for example be bonded to hydrogen atoms in turn as in the case of the cyclohexanyl ring, or two or more bonds may form a carbonyl moiety with a heteroatom, such as an oxygen atom. It is also possible for two adjacent hydrogen atoms to be absent to form a double bond between two adjacent carbon atoms, for example a cyclohexenyl ring. The rings may be substituted by any number of other atoms in addition to the three units of W, X, and Y described below. For the purposes of the present invention, the expression "heterocyclic ring" is defined herein as "ring, which contains at least one atom other than carbon, in particular nitrogen." Non-limiting examples of heterocyclic rings include piperidine, ketopiperazine, ketodiazepines, proline, piperazine, pyrroline, and pyrrolidone.
[64] Non-limiting embodiments of nonaromatic, carbocyclic and heterocyclic rings include the following:
[65]
[66]
[67] Wherein the W, Y and Z units are described below;
[68] T is selected from the group consisting of:
[69] i) -C (R ') _d- ; Wherein each R 'is independently hydrogen, C ₁ -C ₆ linear or branched alkyl, -SUB, and mixtures thereof, and d is an index having a value of 1 or 2;
[70] ii) ;
[71] iii) -NR'-; Wherein R 'is hydrogen, C ₁ -C ₆ linear or branched alkyl, -SUB, or W, Y, or Z units; In some embodiments, R 'is hydrogen, non-limiting examples of which include conformationally limited analogs to a ring having the formula:
[72]
[73] iv) -O-;
[74] V) -S-;
[75] vi) -P (O)-; By way of example, it is associated with conformationally restricted analogs with a ring having the formula:
[76]
[77] J is selected from the group consisting of:
[78] i)-[C (R ") _d ] _k -in which each R" is independently hydrogen, C ₁ -C ₁₂ linear or branched alkyl, -SUB, two R "units are carbonyl together with an oxygen atom Forming a unit, wherein two R "units from any of the J units or R" units and R 'units from the T unit together contain a carbocyclic or heterocyclic fused ring, bicyclic ring, containing 3 to 7 atoms, Or a helical ring; an index d has a value of 1 or 2; an index k has a value of 1 or 2; in one embodiment, at least one J unit contains a -CF ₂ -component. And in other embodiments J has the formula —CH ₂ —, —C (O) —, and mixtures thereof; fused ring embodiments of J include stericly constrained rings having the formula:
[79]
[80] However, R ″ may form a heterocyclic ring, for example a cyclic ether having the formula:
[81]
[82] ii) ;
[83] iii) -NR'-; Wherein R 'is hydrogen, C ₁ -C ₆ linear or branched alkyl, or SUB unit;
[84] iv) -O-;
[85] v) -S-;
[86] vi) -P (O)-or -P (0) _2- ; For example, in combination with other J or T units, the formula: -OP (O)-; -OP (O) R ^30- ; -OP (0) 0-; Or may form moieties having -OP (O) R ³⁰ 0-;
[87] vii) mixtures thereof.
[88] W pendant unit
[89] The W unit of the present invention provides a first pendant unit attached to a three-dimensionally constrained ring. In general, the W unit has the formula:
[90] .
[91] Wherein J is the same as defined above. The W unit of the present invention has several aspects, particularly with respect to the selection of B units, the selection of units containing the framework of the W units, and the selection of R units.
[92] R unit
[93] R is selected from the group consisting of:
[94] a) substituted or unsubstituted non-aromatic carbocyclic ring;
[95] b) substituted or unsubstituted aromatic carbocyclic rings;
[96] c) substituted or unsubstituted nonaromatic heterocyclic rings;
[97] d) substituted or unsubstituted aromatic heterocyclic ring;
[98] Here, the ring contains 3 to 12 elements. Non-limiting examples of aromatic and non-aromatic carbocyclic rings include cyclopropyl, cyclobutanyl, cyclopentanyl, cyclohexane, cyclohexenyl, cycloheptanyl, bicyclo- [0.1.1] -butanyl, bicyclo- [ 0.1.2] -pentanyl, bicyclo- [0.1.3] -hexanyl (investilyl), bicyclo- [0.2.2] -hexanyl, bicyclo- [0.1.4] -heptanyl (caranyl) , Bicyclo- [2.2.1] -heptanyl (norbornanyl), bicyclo- [0.2.4] -octanyl (cariopilenyl), spiropentanil, dicyclopentanepyranyl, decalinyl, phenyl, Benzyl, naphthyl, indenyl, 2H-indenyl, azulenyl, phenanthrenyl, anthracenyl, fluorenyl, acenaphthylenyl, 1,2,3,4-tetrahydronaphthalenyl, and the like. . Non-limiting examples of aromatic and nonaromatic heterocyclic rings include: pyrrolyl, 2H-pyrrolyl, 3H-pyrrolyl, pyrazolyl, 2H-imidazolyl, 1,2,3-triazolyl, 1 , 2,4-triazolyl, isoxazolyl, oxazolyl, 1,2,4-oxadiazolyl, 2H-pyranyl, 4H-pyranyl, 2H-pyran-2-one-yl, pyridinyl, pyrida Genyl, pyrimidinyl, pyrazinyl, piperazinyl, s-triazinyl, 4H-1,2-oxazinyl, 2H-1,3-oxazinyl, 1,4-oxazinyl, morpholinyl, azepinyl , Oxepinyl, 4H-1,2-diazepynyl, indenyl 2H-indenyl, benzofuranyl, isobenzofuranyl, indolyl, 3H-indolyl, 1H-indolyl, benzoxazolyl, 2H- 1-benzopyranyl, quinolinyl, isoquinolinyl, quinazolinyl, 2H-1,4-benzoxazinyl, pyrrolidinyl, pyrrolinyl, quinoxalinyl, pyrrolyl, furanyl, thiophenyl, Benzimidazolyl and the like. Each of these rings may be suitably substituted by one or more -SUB units.
[99] In one embodiment of the invention the R unit is a phenyl and substituted phenyl ring, in particular 3-fluorophenyl, 4-fluorophenyl, 3,5-difluorophenyl, 4-chlorophenyl, and 4-hydroxyphenyl to be.
[100] In another embodiment of the invention the R unit is substituted or unsubstituted phenyl, α-naphthyl, β-naphthyl, 1-quinolinyl, 2-quinolinyl, 3-quinolinyl, 4-quinolinyl , 5-quinolinyl, 6-quinolinyl, 7-quinolinyl, 8-quinolinyl, 1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 1-pyridinyl, 2- Encompassing rings selected from the group consisting of pyridinyl, 3-pyridinyl, or 4-pyridinyl.
[101] Other embodiments contain R units that are phenyl, α-naphthyl, or β-naphthyl.
[102] L unit
[103] L is a linker, which is provided to link two or more units of conformationally restricted receptor ligands. The following definitions of L units apply to linkers throughout the present invention. The linking groups of the present invention contain any atom or group of atoms, which suitably connect two or more units. One example of a suitable L unit group relates to the "peptide bond, carbonyl, and modified carbonyl unit" group of linking units. In one or more embodiments of the invention, the L units may be absent.
[104] Non-limiting examples of L units from this group of peptide bonds, carbonyl and modified carbonyl units are selected from the group consisting of:
[105]
[106] Wherein R ¹¹ is hydrogen, linear or branched C ₁ -C ₁₀ alkyl, hydroxyl, —SUB, or mixtures thereof; R ¹² is C ₁ -C ₁₆ linear or branched, substituted or unsubstituted alkylene, substituted or unsubstituted phenylene, or a mixture thereof; Or R ¹¹ and R ¹² units may form a ring together; X is oxygen, sulfur, = NR ¹¹ , and mixtures thereof; t is 0 or 1;
[107] The following relates to one embodiment of L units:
[108]
[109] The following relates to another embodiment of L units:
[110]
[111] Other embodiments of the present invention may use only -NH- moieties as linking units, while in other embodiments both -C (O) NH- and -NHC (O)-may be used. However, additional embodiments are evenly selected from the following L units:
[112]
[113] Other embodiments may contain a combination of carbonyl and modified carbonyl L units, eg, units having the following formulas:
[114]
[115] Or only modified carbonyl having the formula:
[116] .
[117] Examples of L units in which R ¹¹ and R ¹² , two R ¹¹ units or two R ¹² units together form a ring, are three-dimensionally constrained L units:
[118]
[119] However, the rings formed by R ¹¹ and R ¹² may also contain one or more heteroatoms, eg, linking units having the formula:
[120] .
[121] B units
[122] The B units of the present invention encompass several distinct aspects, each having a number of embodiments that depend on the requirements set by the formulator for the receptor ligand.
[123] B units do not require a chiral center, but many embodiments of B described herein contain a chiral center. Some non-limiting embodiments of B with chiral and achiral centers are listed below.
[124] Formulators of the MC-4, MC-3, and MC-4 and MC-3 receptor ligands are one of the R ² , R ³ and R ⁴ units if any two R ² , R ³ and R ⁴ are identical It will be appreciated that B will not have a chiral center if it does not contain a chiral center, or if R ² , R ³ or R ⁴ together form a ring with a chiral center. B units are represented by the following formula:
[125]
[126] [Wherein, R ² , R ³ and R ⁴ are described below].
[127] The first aspect of B relates to units in which the R ² , R ³ and R ⁴ units are independently selected from the group:
[128] A) Rings containing:
[129] a) substituted or unsubstituted aromatic carbocyclic ring;
[130] b) substituted or unsubstituted aromatic heterocyclic ring;
[131] c) and mixtures thereof;
[132] B) hydrogen;
[133] C) SUB unit; And
[134] D) mixtures thereof.
[135] Non-limiting examples of substituted or unsubstituted rings according to (A) above include: benzyl, 4-hydroxybenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 3,5-dichlorobenzyl, 4-fluoro Lobenzyl, (imidazol-2-yl) methyl, (imidazol-4-yl) methyl, 2-phenylethyl, 2- (4-hydroxyphenyl) ethyl, 3- (r-hydroxyphenyl) propyl, and the like .
[136] In certain embodiments of the first aspect of B units, the B units contain chiral units having the formula:
[137]
[138] In the formula, R ² and R ³ are each independently hydrogen, -C (X) N (R ¹³ ) ₂ ; -N (R ¹³ ) ₂ ; _{^{-N + (R 13) 3 D}} -; ^{-C (X) N + (R} 13) 3 D -; -NR ¹³ C (X) R ¹⁴ ; And mixtures thereof; With the proviso that R ² and R ³ are not the same; R ¹³ is hydrogen, C ₁ -C ₁₀ alkyl, or mixtures thereof; R ¹⁴ is C ₁ -C ₁₆ linear or branched, substituted or unsubstituted alkyl, C ₇ -C ₁₆ linear or branched, substituted or unsubstituted alkylenearyl; X is oxygen, sulfur, = NR ¹³ , and mixtures thereof; D is a salt forming anion; R ⁴ is C ₇ -C ₁₆ substituted or unsubstituted alkylarylene, in particular benzyl and substituted benzyl. Specific examples of R ² and R ³ include —CH ₂ C (O) CH ₃ , —NHC (O) CH ₃ , —NHC (O) CH ₂ CH ₃ , and —NHC (O) CH ₂ CH ₂ CH ₃ . Include.
[139] One aspect of W contains units having the formula:
[140] .
[141] Wherein J has-(CH ₂ )-, -C (O)-and mixtures thereof;
[142] L units are selected from the group consisting of:
[143]
[144] R is substituted or unsubstituted aryl;
[145] B is hydrogen or a unit having the formula:
[146] ,
[147] Wherein R ² , R ³ and R ⁴ units are independently selected from:
[148] a) a ring containing:
[149] i) a substituted or unsubstituted aromatic carbocyclic ring;
[150] ii) substituted or unsubstituted aromatic heterocyclic ring;
[151] iii) and mixtures thereof;
[152] b) hydrogen;
[153] c) a unit selected from the group consisting of -CH ₂ C (O) CH ₃ , -NHC (O) CH ₃ , -NHC (O) CH ₂ CH ₃ , and -NHC (O) CH ₂ CH ₂ CH ₃ :
[154] d) at least two of R ² , R ³ or R ⁴ together may form a ring;
[155] e) mixtures thereof.
[156] A particular embodiment of this aspect of B contains the R ² units having the R ¹⁴ is hydrogen and R ³ units of formula -NR ¹³ C (X) [in the formula, R ¹⁴ is C ₁ -C ₄ linear alkyl; do. In one particular series of embodiments of R ^2, R ² is _{-NHC (O) CH 3, R} 3 is hydrogen the other hand, R ⁴ is benzyl, 4-hydroxybenzyl, 4-chlorobenzyl, 4- While one or more units are selected from the group consisting of methoxybenzyl, 3-nitrobenzyl, and mixtures thereof, another embodiment includes these two units and benzyl, 2-imidazolylmethyl, 4-imida. R ⁴ units selected from the group consisting of zolylmethyl, 4-fluorobenzyl, 4-hydroxybenzyl, and 4-acetoxybenzyl. These embodiments of this aspect are further illustrated in the analogue tables below.
[157] Embodiments of this aspect can readily utilize L-amino acids and derivatives thereof as a source of B units.
[158] One embodiment of this aspect of the W units relates to coupling a B unit derived from L-amino acid with an R unit derived from D-amino acid. As an example, the W unit containing the diamino acid residue N-acetyltyrosinyl-D-phenylalanine (N-acetyl-Yf) has the formula:
[159]
[160] In the formula, J is -C (O) -, J ^* is -CH ₂ -, R is phenyl, L is -NHC (O) - is a.
[161] Another embodiment of this aspect of the invention relates to B units, which can be conveniently obtained from D-amino acids as a source of chiral carbon atoms, for example B units having the formula:
[162] ,
[163] Wherein R ³ is hydrogen; R ² is at least one unit selected from the group consisting of benzyl, 4-hydroxybenzyl, 4-chlorobenzyl, 4-methoxybenzyl, 3-nitrobenzyl, and mixtures thereof; R ⁴ is -C (O) N (H) 2, -N (H) 2 -N + (H) 3 D -, -C (O) N + (R 14) 3 D -, -NHC (O) R ¹⁴ is a unit selected from and mixtures thereof; R ¹⁴ is a C ₇ -C ₁₆ substituted or unsubstituted alkylarylene unit, non-limiting examples of which are benzyl, 4-hydroxybenzyl, 2-phenylethyl, 3-phenylethyl, 2- (4-hydroxy Phenyl) ethyl and the like; D is a salt forming anion.
[164] One embodiment of the W unit relates to a compound containing a primary amino unit, eg, a W unit having the formula:
[165] .
[166] Wherein the SUB unit represents one or more substitutions for hydrogen atoms as defined herein above. Other non-limiting examples of this embodiment include:
[167]
[168] Another aspect of the invention relates to a B unit which, together with a sulfonamide linking unit, provides a receptor having a W unit of the formula:
[169] .
[170] Wherein R ² , R ³ and R ⁴ are as defined above. One embodiment of this aspect relates to a receptor ligand, wherein two or more R ² , R ³ or R ⁴ together form a ring, or R ⁴ contains an aryl or heteroaryl group, wherein the units are phenyl, benzyl, 2-phenethyl, naphthyl, naphthalen-2-ylmethyl, naphthalen-2-ylethyl, and 6-hydroxynaphthalen-2-ylmethyl, and non-limiting examples thereof include Contains scaffolds with:
[171] .
[172] In the formula, R, R ⁹ and R ¹⁵ represent any component described herein.
[173] Another aspect of the invention relates to a B unit, wherein at least one, preferably at least ^two , of R ² , R ³ or R ⁴ units contain a hydrogen bonding unit selected from the group:
[174] A) C ₁ -C ₁₂ linear or branched alkyl units substituted by one or more hydrogen bond SUB ′ units;
[175] B) C ₂ -C ₁₂ linear or branched alkenyl units substituted by one or more hydrogen bond SUB ′ units;
[176] C) hydrogen;
[177] D) SUB 'units; And
[178] E) mixtures thereof;
[179] The SUB 'units here are "substituents for hydrogen containing units which are hydrogen bonding units".
[180] Non-limiting examples of -SUB 'units are selected from the group consisting of:
[181] .
[182] Non-limiting examples of W units containing B units having two or more hydrogen bond units have the formula:
[183]
[184] Another aspect of the B units contains R ² , R ³ and R ⁴ units, one of which contains a hydrogen bond unit attached to the ring, or two or three of R ² , R ³ and R ⁴ units Together form a ring, examples of which have the general formula:
[185] .
[186] Further examples of this aspect of the W units have the formula:
[187]
[188]
[189] Y unit has the formula:
[190] -LR ¹⁵ ,
[191] In the formula, R ¹⁵ has a heteroatom containing group.
[192] The first aspect of the Y unit relates to short chain alkyl or alkenyl (lower hydrocarbyl) esters having the formula:
[193] -(CH ₂ ) _b -R ¹⁵ .
[194] Wherein the index b is 1-4; R ¹⁵ is a linear ester or amide, non-limiting examples of which include: —C (O) OCH ₃ ; -C (O) OCH ₂ CH ₃ ; -C (O) OCH ₂ CH ₂ CH ₃ ; -C (O) OCH ₂ CH ₂ CH ₂ CH ₃ ; -C (O) OCH (CH ₃ ) ₂ ; -C (O) OCH ₂ CH (CH ₃ ) ₂ ; —C (O) OCH ₂ CH═CHCH ₃ ; -C (O) OCH ₂ CH ₂ CH (CH ₃ ) ₂ ; C (O) OCH ₂ C (CH ₃ ) ₃ ; -OC (O) CH ₃ ; -OC (O) CH ₂ CH ₃ ; -OC (O) CH ₂ CH ₂ CH ₃ ; -OC (O) CH (CH ₃ ) ₂ ; -OC (O) CH ₂ CH ₂ CH ₂ CH ₃ ; -OC (O) CH ₂ CH (CH ₃ ) ₂ ; -OC (O) CH ₂ CH = CHCH ₃ ; -OC (O) CH ₂ C (CH ₃ ) ₃ ; -OC (O) CH ₂ CH ₂ CH (CH ₃ ) ₂ ; Etc; And short chain substituted or unsubstituted amides, non-limiting examples of which are: -C (O) NHCH ₃ ; -C (O) NHCH ₂ CH ₃ ; -C (O) NHCH (CH ₃ ) ₂ ; -C (O) NHCH ₂ CH ₂ CH ₃ ; -C (O) NHCH ₂ CH ₂ CH ₂ CH ₃ ; -C (O) NHCH ₂ CH (CH ₃ ) ₂ ; -C (O) NH ₂ ; C (O) NHCH ₂ CH = CHCH ₃ ; -C (O) NHCH ₂ CH ₂ CH (CH ₃ ) ₂ ; -C (O) NHCH ₂ C (CH ₃ ) ₃ ; -C (O) NHCH ₂ CH ₂ SCH ₃ ; -C (O) NHCH ₂ CH ₂ 0H; -NHC (O) CH ₃ ; -NHC (O) CH ₂ CH ₃ ; -NHC (O) CH ₂ CH ₂ CH ₃ ; -NHC (O) CH ₃ ; -NHC (O) CH ₂ CH ₃ ; -NHC (O) CH (CH ₃ ) ₂ ; -NHC (O) CH ₂ CH ₂ CH ₃ ; NHC (O) CH ₂ CH ₂ CH ₂ CH ₃ ; -NHC (O) CH ₂ CH (CH ₃ ) ₂ ; -NHC (0) ₂ ; —NHC (O) CH ₂ CH═CHCH ₃ ; NHC (O) CH ₂ CH ₂ CH (CH ₃ ) ₂ ; -NHC (O) CH ₂ C (CH ₃ ) ₃ ; -NHC (O) CH ₂ CH ₂ SCH ₃ ; NHC (O) CH ₂ CH ₂ 0H; -NHC (O) CH ₃ ; -NHC (O) CH ₂ CH ₃ ; -NHC (O) -CH ₂ CH ₂ CH ₃ ; Etc.
[195] The second aspect of the Y units contains guanidine and guanidine analogs having the formula:
[196] -(CH ₂ ) _z -R ¹⁵ .
[197] Wherein R ¹⁵ is a unit selected from the group consisting of:
[198]
[199] Wherein X is = O, = S, NR ¹⁶ , and mixtures thereof, and R ¹⁶ is hydrogen, methyl, cyano, hydroxy, nitro, and mixtures thereof; The index z is 0-5.
[200] Non-limiting examples of R ¹⁵ units containing this second aspect of the Y unit include:
[201] .
[202] A third aspect of the invention with respect to Y units contains a 5-membered heterocyclic ring, wherein R ⁵ is selected from the group consisting of:
[203] i) triazoles having the formula:
[204]
[205] ii) tetrazolyl having the formula:
[206]
[207] iii) thiazolyl, 2-methylthiazolyl, 4-methylthiazolyl, 5-methylthiazolyl having the formula:
[208]
[209] iv) 1,3,4-thiadiazolyl, 2-methyl-1,3,4-thiadiazolyl having the formula:
[210]
[211] v) 1,2,5-thiadiazolyl, 3-methyl-1,2,5-thiadiazolyl having the formula:
[212]
[213] vi) oxazolyl, 2-methyloxazolyl, 4-methyloxazolyl, 5-methyloxazolyl having the formula:
[214]
[215] vii) imidazolyl, 2-methylimidazolyl, 5-methylimidazolyl having the formula:
[216]
[217] viii) 5-methyl-1,2,4-oxadiazolyl, 2-methyl-1,3,4-oxadiazolyl, 5-amino-1,2,4-oxadiazolyl having the formula:
[218]
[219] ix) 1,2-dihydro [1,2,4] triazol-3-one-1-yl, 2-methyl-1,2-dihydro [1,2,4] triazole- having the formula 3-on-5-day:
[220]
[221] x) oxazolidin-2-one-3-yl having the formula: 4,4-dimethyloxazolidin-2-one-3-yl; Imidazolidin-2-one-1-yl; 1-methylimidazolidin-2-one-1-yl:
[222]
[223] xi) 2-methyl-1,3,4-oxadiazolyl, 2-amino-1,3,4-oxadiazolyl, 2- (N, N-dimethylamino) 1,3,4- having the formula Oxadiazolyl:
[224]
[225] These R ¹⁵ units consist of:
[226] i)-[C (R ¹¹ ) ₂ ] _p- , wherein p is 0 to 12; And
[227] ii) -R ¹² NR ^11- ;
[228] Together with the L unit selected from form a heterocyclic Y unit, non-limiting examples of which include the following formula:
[229] .
[230] A fourth aspect of the Y unit relates to the moiety wherein R ¹⁵ contains a 6 membered heterocyclic ring, non-limiting examples of which include:
[231] i) pyridinyl units having the formula:
[232]
[233] ii) pyrimidinyl units having the formula:
[234]
[235] ii) piperidinyl units having the formula:
[236]
[237] Another aspect of the invention relates to an R ¹⁵ unit that is -NH ₂ , and -OH.
[238] However, in the broad sense, when taken together with a linking group having — (CH ₂ ) _p −, where p is 0 to 12, R ¹⁵ is amino, guanidino, guanyl, amidino, pyrrolyl , 2H-pyrrolyl, 3H-pyrrolyl, pyrazolyl, 2H-imidazolyl, 1,2,3-triazole, 1,2,4-triazole, isoxazolyl, oxazolyl, 1,2,3 Isoxazolyl, 1,2,4-oxadiazolyl, 2H-pyranyl, 4H-pyranyl, 2H-pyran-2-one-yl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, py Ferrazinyl, s-triazinyl, 4H-1,2-oxazinyl, 2H-1,3-oxazinyl, 1,4-oxazinyl, morpholinyl, azefinyl, oxepinyl, 4H-1,2 Diazefinyl, indenyl, 2H-indenyl, benzofuranyl, isobenzofuranyl, indolyl, 3H-indolyl, 1H-indolyl, benzoxazolyl, 2H-1-benzopyranyl, quinolinyl Isoquinolinyl, quinazolinyl, 2H-1,4-benzoxazinyl, pyrrolidinyl, pyrrolidoneyl, pyrrolinyl, quinoxalinyl, pyrrolyl, benzimidazolyl, and horns thereof It may be any units selected from the group consisting of combinations.
[239] Z unit
[240] Z unit has the formula:
[241] .
[242] Wherein R ⁸ and R ⁹ are each independently
[243] i) hydrogen;
[244] ii) substituted or unsubstituted phenyl;
[245] iii) C ₇ -C ₁₆ substituted or unsubstituted alkylarylene;
[246] iv) naphthyl;
[247] v) quinolinyl;
[248] vi) imidazolyl;
[249] vii) indolyl;
[250] viii) pyridinyl;
[251] ix) a substituted or unsubstituted non-aromatic carbocyclic ring of C ₃ -C ₁₀ ;
[252] x) a substituted or unsubstituted non-aromatic heterocyclic ring of C ₂ -C ₁₀ ; And
[253] xi) mixtures thereof;
[254] R ¹⁰ is hydrogen, -C (X) N (R 16) 2, -N (R 16) 2 -N + (R 16) 3 D -, -C (X) N + (R 16) 3 D -, -NR ¹⁶ C (X) R ¹⁷ and mixtures thereof; R ¹⁶ is hydrogen, C ₁ -C ₁₀ alkyl, or a mixture thereof; R ¹⁷ is C ₁ -C ₁₆ linear or branched, substituted or unsubstituted alkyl, C ₇ -C ₁₆ linear or branched, substituted or unsubstituted alkylenearyl; X is oxygen, sulfur, = NR ¹⁶ , and mixtures thereof, and D is a salt forming anion.
[255] In one embodiment of the invention, R ⁸ is hydrogen; R ⁹ is indolyl or naphthyl; R ¹⁰ is —NHC (O) CH ₃ .
[256] However, Z units may contain chiral centers represented by the formula:
[257] ,
[258] Wherein R ⁸ , R ⁹ and R ¹⁰ are the same as defined above.
[259] Another embodiment of the present invention contains Z units, which are tethered to a ring component that is conformationally constrained by T units containing -O-, -NH-, -S- and the like, Has:
[260] .
[261] Wherein R ⁸ , R ⁹ , and R ^1O are each independently
[262] i) hydrogen;
[263] ii) substituted or unsubstituted phenyl;
[264] iii) C ₇ -C ₁₆ substituted or unsubstituted alkylarylene;
[265] iv) naphthyl;
[266] v) quinolinyl;
[267] vi) imidazolyl;
[268] vii) indolyl;
[269] viii) pyridinyl;
[270] ix) and mixtures thereof.
[271] In one embodiment of this T unit containing a tether, R ⁸ and R ⁹ are each hydrogen and R ¹⁰ is selected from:
[272] i) substituted or unsubstituted phenyl;
[273] ii) C ₇ -C ₁₆ substituted or unsubstituted alkylarylene;
[274] iii) naphthyl, α or β linked;
[275] iv) quinolinyl;
[276] v) imidazolyl;
[277] vi) indolyl;
[278] vii) pyridinyl;
[279] viii) and mixtures thereof.
[280] Receptor Ligands and Embodiments
[281] One aspect of the invention relates to a combination of different aspects of W pendant units and various Y and Z pendant units having various conformationally limited A rings. Some aspects of the W unit contain a di-peptide backbone, di-peptide, or di-peptide analog. Such variants of W may be combined with stereoscopically constrained rings of any size, such as 5, 6 and 7 membered rings, providing a receptor ligand scaffold having the formula:
[282]
[283] Wherein R is a unit containing at least one aromatic ring. This embodiment of the present invention describes a wide range of independent substituents that the formulator can make at the F and G positions relative to the size of the A ring and Y and Z pendant units. In this example, the G units may be the side chains of amino acids, while the F units may be the hydrogen of a suitable capping group.
[284] In a first embodiment of this aspect, R is an aryl unit and W is a di-peptide analog containing G and F units as defined below herein.
[285] F units contain:
[286] a) hydrogen;
[287] b) SUB unit; Non-limiting examples of these include:
[288] i) -NHC (X) R ³⁰ ;
[289] ^{ii) -C (X) R 3O} ;
[290] iii) -C (X) N (R ³⁰ ) ₂ ;
[291] iv) -R ³⁰ ; Wherein R ³⁰ is C ₁ -C ₂₂ linear or branched, substituted or unsubstituted alkyl; C ₃ -C ₂₂ linear or branched, substituted or unsubstituted cycloalkyl; C ₂ -C ₂₂ linear or branched, substituted or unsubstituted alkenyl; C ₃ -C ₂₂ linear or branched, substituted or unsubstituted cycloalkenyl; C ₁ -C ₂₂ linear or branched, substituted or unsubstituted heteroalkyl; C ₁ -C ₂₂ linear or branched, substituted or unsubstituted cycloheteroalkyl; C ₂ -C ₂₂ linear or branched, substituted or unsubstituted heteroalkenyl; C ₂ -C ₂₂ linear or branched, substituted or unsubstituted cycloheteroalkenyl; And mixtures thereof.
[292] G unit contains:
[293] a) C ₆ -C ₁₂ substituted or unsubstituted aryl; By way of example, phenyl, 4-hydroxyphenyl, 4-methylphenyl, naphthyl;
[294] b) C ₆ -C ₁₂ substituted or unsubstituted heteroaryl C ₆ -C ₁₂ substituted or unsubstituted heteroaryl; For example, indolyl;
[295] c) C ₇ -C ₁₇ substituted or unsubstituted alkylenearyl; By way of example, benzyl, 4-hydroxybenzyl;
[296] d) C ₃ -C ₁₇ substituted or unsubstituted alkyleneheteroaryl; And
[297] e) mixtures thereof.
[298] However, one aspect of di-peptide analog embodiments relates to non-peptide backbones, for example receptor ligand scaffolds having the formula:
[299] .
[300] The present invention also contains several aspects relating to the presence of a 4-carbon atom steric structurally constrained linking di-peptide W units or di-peptide analog W units and Z units.
[301] One embodiment of the invention for analogs having 4-atomic segments connecting W and Z units has the following general formula:
[302] .
[303] Wherein T is -CH-, -N-, and mixtures thereof; R, J, L, Y, B and Z are the same as defined above herein; The index n is 1-4.
[304] For this embodiment of a 4-carbon atom segment, the -J ^* R units together may be C ₁ -C ₁₂ linear or branched alkyl; C ₆ -C ₁₂ substituted or unsubstituted aryl; C ₆ -C ₁₂ substituted or unsubstituted heteroaryl; C ₇ -C ₁₇ substituted or unsubstituted alkylenearyl; C ₃ -C ₁₇ substituted or unsubstituted alkyleneheteroaryl; And units selected from the group consisting of mixtures thereof.
[305] Another example of this aspect has the formula:
[306] .
[307] Wherein R, J, L, J ^* , T, Y, B and Z are the same as defined above herein; The index n is 1-4.
[308] One aspect of the receptor ligands of the present invention is a conformationally limited 4-amino acid containing a peptide or peptide analog having YfRW as the core amino acid component, [tyrosinyl-D-phenylalanylarginylyltryptopamide (Tyr- D-Phe-Arg-Trp-NH ₂ )], which has a primary template having the general formula:
[309] ,
[310] Wherein the T unit at the 4-position is -NH; The J units in the 3- and 6-positions are each -C (O)-, thus providing a stereoscopically restricted ring having the formula:
[311] .
[312] Another embodiment of the tyrosinyl-D-phenylalanyl moiety containing W units relates to compounds that are, for example, receptor ligands having the formula:
[313] .
[314] Another variant of the conformational limitation of tetrapeptides is histidinyl-D-phenylalanylargininyltryptopamide (His-D-Phe-Arg-Trp-NH ₂₎ , a four- residue peptide having HfRW as the core amino acid component. ), Which is conformationally limited and optionally further modified to form one or more primary molds having the general formula:
[315] ,
[316] Wherein W is His-D-Phe-part. Due to the presence of histidine amino acid units as part of the W units, this embodiment contains B units with heterocyclic R ⁴ units, which encompass aspects of the B units with respect to the conformationally limited hydrogen bond B units. Variants of this ring structure with modified Y and Z units and J units include one embodiment of the invention as reflected in the examples listed below.
[317] The following are non-limiting examples of embodiments of such conformationally limited templates:
[318] .
[319] Another embodiment of the invention relates to 5-membered rings MC4 and MC4 and / or MC3 receptor ligands, for example ligands having a conformationally restricted template having the formula:
[320] ,
[321] This is modified to provide the following non-limiting examples of the receptor ligands:
[322] .
[323] The following is a non-limiting description of some embodiments of the present invention. The following is the key to a contiguous table of conformationally restricted MC-4, MC-3 and MC-4 and MC-3 receptor ligands.
[324] The following are non-limiting examples of stericly constrained rings showing the positions of the W, Y and Z units.
[325]
[326]
[327] One embodiment of the invention contains 3-guanidinopropyl Y units attached to the A-W rings, while another aspect of the invention substitutes the following Y units with 3-guanidinopropyl. Y units are selected from the group consisting of:
[328]
[329] The first category of receptor ligands according to the invention relates to conformationally restricted rings containing pyrrolidine scaffolds having the formula:
[330] .
[331] In the formula, each carbon indicated by an asterisk has an arbitrary configuration. Table I relates to non-limiting examples of analogs containing the first aspect of the category, which analogs have the formula:
[332] .
[333] Wherein R, R ² , R ³ , R ⁴ and R ⁹ are defined in Table I, but 3-aminopropyl intermediates as described in Example 1 are also suitable receptor ligand analogs, repeating this aspect of the invention Indicates.
[334]
[335]
[336]
[337] The following is an overview of the synthetic route to prepare analogs 1-60, but other embodiments of pyrrolidone scaffolds can be made by modifying this general method.
[338]
[339] Reagents and Conditions:
[340] (a) (Boc) ₂ 0, TEA, 0 ° C to room temperature;
[341] (b) TMEDA, sec-BuLi, -78 ° C to -40 ° C; CH ₂ = CHCH ₂ Br, −78 ° C. to room temperature.
[342]
[343] Reagents and Conditions:
[344] (c) NaH, PhCH ₂ Br (analogs 60-88), NaphCH ₂ Br (analogs 61-120), 0 ° C. to room temperature.
[345]
[346] Reagents and Conditions:
[347] (d) BH ₃ -THF, H ₂ O ₂ / NaOH, room temperature;
[348] (e) CH ₃ SO ₂ Cl, TEA, 0 ° C. to room temperature.
[349]
[350] Reagents and Conditions:
[351] (f) NaN ₃ , 70 ° C .;
[352] (g) TFA-H ₂ 0-CH ₂ Cl ₂ , room temperature.
[353]
[354] Reagents and Conditions:
[355] (h) Boc-D-Phe (analog 1, 8, 15, 22, 29, 36, 43, 50, 58 and 6O), Boc-homo-D-Phe (analog 2, 9, 16, 23, 30, 37, 44 and 5L), Boc-D-Phe (3-F) (analog 3, 10, 17, 24, 31, 38, 45 and 52), Boc-D-Phe (4-F) (analog 4, 11, 18, 25, 32, 39, 46, 53, 57 and 59), Boc-D-Phe (3,5-F) (analog 5, 12, 19, 26, 33, 40, 47 and 54), Boc-D-Phe (4-Cl) (analog 6, 13, 20, 27, 34, 41, 48, and 55), Boc-D-Phe (4-OH) (analog 7, 14, 21, 28, 35 , 42, 49, and 56); 1-hydroxybenzotriazole, N -methylmorpholine, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide, room temperature.
[356]
[357] Reagents and conditions: (i) TFA-H ₂ 0-CH ₂ Cl ₂ , room temperature.
[358]
[359] Reagents and Conditions:
[360] (j) AcNHCH (CH ₂ Phe) CO ₂ H (analogues 1-7, 29-35, 57 and 58); N-Ac-histidine (analogues 8-14 and 36-42; AcNHCH [CH ₂ Phe (4-Cl)] CO ₂ H (analogues 15-21, 43-49), N- Ac-tyrosine (analogue 22-28 , 50-56 and 59); AcNHCH (CH ₂ Naph) CO ₂ H (analogue 60); 1-hydroxybenzotriazole, N -methylmorpholine, 1- (3-dimethylaminopropyl) -3-ethylcarb Bodyimide, room temperature.
[361]
[362] Reagents and Conditions:
[363] (k) H ₂ , Pd / C.
[364]
[365] Reagents and Conditions:
[366] (l) BocNHC (SCH ₃ ) = NBoc, HgCl ₂ , room temperature.
[367]
[368] Reagents and Conditions:
[369] (m) TFA: CH ₂ Cl ₂ : anisole, room temperature.
[370] Preparation of Pyrrolidone Synthetic Intermediates
[371] The following is a process for preparing the pyrrolidone scaffold intermediate having the formula:
[372]
[373] In this example here, R ⁹ is a 2-naphthyl moiety.
[374] 2- S -(3-azidopropyl) -4- R -(Naphthalen-2-ylmethoxy) -pyrrolidine
[375] Preparation of N- Boc-3- R -hydroxypyrrolidine (1): di- tert -butyl dicarbonate (14.0 g, 63.1 mmol) dissolved in dichloromethane (58 ml) at 0 ° C. To a stirred solution of R -hydroxypyrrolidine (5.0 g, 57.4 mol) and triethylamine (16 mL, 114.8 mmol). The resulting solution was allowed to warm to rt and stirred for 4 h. The solution was then diluted with dichloromethane (50 mL), washed twice with 1 N HCl and twice with aqueous NaHCO ₃ solution. The organic layer was then dried over Na ₂ SO ₄ , filtered and concentrated in vacuo to afford the desired product (9.9 g, 92%) as a white solid, which was pure enough to be used without further purification.
[376] Preparation of N- Boc-2- S -allyl-4- R -hydroxypyrrolidine (2): N- Boc-3- R -hydroxypyrrolidine, 1 , (3.0 g, 16.0 mmol), And a solution of TMEDA (6.4 mL, 40.1 mmol) was dissolved in THF (50 mL) and cooled to -78 ° C. This reaction mixture was added to a solution of 1.3 M sec -butyl lithium (50 mL) in cyclohexane while stirring. The resulting orange mixture was allowed to warm to -40 ° C and stirred for 2.75 hours. The mixture was again cooled to -78 ° C and allyl bromide (3.1 mL, 35.3 mmol) was added. The mixture was stirred for 4.5 hours and slowly warmed to room temperature. The reaction was quenched with aqueous NH ₄ Cl solution and extracted with ethyl acetate (150 mL). The organic layer was then dried over Na ₂ SO ₄ , filtered and concentrated in vacuo. The oily residue was purified on silica gel (CH ₂ Cl ₂ / acetone, 3: 1) to afford the desired product (2.0 g, 56%) as a clear oil.
[377] Preparation of N- Boc-2- S- allyl-4- R- (naphthalen-2-ylmethoxy) pyrrolidine (3): Sodium hydride (408 mg, 11.5 mmol) is N- Boc in DMF at 0 ° C. To a stirred solution of -2- S -allyl-4- R -hydroxypyrrolidine, 2 , (2.0 g, 8.8 mmol) was added in portions and the reaction mixture was stirred for 20 minutes. 2- (bromomethyl) naphthalene (2.9 g, 13.2 mmol) in DMF (5 mL) was then added and the resulting solution was stirred at rt for 5 h. The reaction was quenched with aqueous NH ₄ Cl solution and extracted twice with ethyl acetate. Layers were dried over Na ₂ S0 ₄ , filtered and concentrated in vacuo to afford a yellow oil. The oil residue was purified on silica gel (hexane / EtOAc, 6: 1) to afford the desired product (2.7 g, 84%) as a clear oil.
[378] Preparation of N- Boc-2- S- (3-hydroxypropyl) -4- R- (naphthalen-2-ylmethoxy) pyrrolidine (4): Borane-tetra in THF (11 mL, 11 mmol) 1.0 M solution of hydrofuran complex was added with N- Boc-2- S -allyl-4- R- (naphthalen-2-ylmethoxy) pyrrolidine, 3 , (2.7 g, 7.3 mmol) in THF (15 mL). To the solution was added slowly, the reaction mixture was stirred for 0.5 h, after which time H ₂ 0 (4.1 ml) was carefully added, 3.0 M NaOH (7.3 mL) and 33% H ₂ 0 ₂ (5.0 mL) were added. Added. The mixture was stirred for 2 hours and then extracted with EtOAc (50 ml). The organic layer was dried over Na ₂ SO ₄ , filtered and concentrated in vacuo to afford a yellow oil. The oily residue was purified on silica gel (hexanes / EtOAc, 1: 1) to afford the desired product (712 mg) as an oil.
[379] Preparation of N- Boc-2- S- (3-methanesulfonyloxypropyl) -4- R- (naphthalen-2-ylmethoxy) pyrrolidine (5): methane sulfonyl chloride (0.215 mL, 2.8 mmol) At 0 ° C. N- Boc-2- S- (3-hydroxypropyl) -4- R- (naphthalen-2-ylmethoxy) pyrrolidine, 4 , (712 mg) in dichloromethane (6 mL), And triethylamine (0.39 mL, 2.8 mmol) was added and the reaction mixture was stirred at room temperature for 0.75 hours. The reaction was quenched with saturated aqueous NaHCO ₃ and extracted twice with dichloromethane (25 mL). The combined organic layers were dried over Na ₂ S0 ₄ , filtered and concentrated in vacuo to afford the desired product (856 mg, 100%) as an oil, which was pure enough for use without further purification.
[380] Preparation of N- Boc-2- S- (3 -azidopropyl ) -4- R- (naphthalen-2-ylmethoxy) pyrrolidine (6): Sodium azide (361 mg, 5.50 mmol) was dissolved in DMSO ( To a solution of N- Boc-2- S- (3-methanesulfonyloxypropyl) -4- R- (naphthalen-2-ylmethoxy) pyrrolidine, 5 , (856 mg, 1.85 mmol) in 7 mL). Was added and the reaction mixture was stirred at 70 ° C. for 3 hours. The reaction was quenched with H ₂ 0 and extracted with EtOAc (30 mL). The extract was dried over Na ₂ S0 ₄ , filtered and concentrated in vacuo to give an orange oil. The oily residue was purified on silica gel (hexanes / EtOAc, 3: 1) to give the desired product (584 mg, 78%) as a colorless oil.
[381]
[382] Preparation of 2- S- (3 -azidopropyl ) -4- R- (naphthalen-2-ylmethoxy) pyrrolidine (7): TFA: H ₂ 0: CH ₂ Cl ₂ (1: 0.1: 1, 20 mL) was rounded with N- Boc-2- S- (3-azidopropyl) -4- R- (naphthalen-2-ylmethoxy) pyrrolidine, 6 , (2.85g, 6.95 mmol) To the flask was added and the reaction mixture was stirred for 1 hour. The mixture was concentrated in vacuo to afford the desired product (3.0 g, 100%) as a TFA salt. Crude oil was provided as an intermediate of the synthetic embodiments of the present invention without further purification.
[383] Pyrrolidine synthetic intermediates having the formula:
[384] ,
[385] It can be prepared by substituting benzyl bromide with 2- (bromomethyl) naphthalene under the conditions described above for the preparation of compound 3.
[386] Example 1
[387] 2- S -Acetylamino- N -{2- [2- S -(3-aminopropyl) -4- R -(Naphthalen-2-ylmethoxy) -pyrrolidin-1-yl] -1- R -Benzyl-2-oxo-ethyl} -3- (4-hydroxyphenyl) propionamide (11)
[388] 2- S - N- ( tert -butoxycarbonyl) amino-1- [2- (3 -azidopropyl ) -4- R- (naphthalen-2-ylmethoxy) -pyrrolidin-1-yl] Preparation of -3-phenylpropan-1-one (8): 2- S- (3-azidopropyl) -4- R- (naphthalen-2-ylmethoxy) pyrrolidine (1.0 in DMF (9.4 mL) g, 2.36 mmol), N- ( tert -butoxycarbonyl) -D-phenylalanine (625 mg, 2.36 mmol), 1-hydroxybenzotriazole (641 mg, 4.72 mmol) and N -methylmorpholine (0.8 mL, 7.07 mmol) was added 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (506 mg, 2.83 mmol) and the mixture was stirred at rt for 1.25 h. The reaction was quenched with saturated aqueous NH ₄ Cl solution and extracted with EtOAc (75 mL). The organic layer was washed with H ₂ 0 (100 mL), brine (100 mL), dried over Na ₂ SO ₄ , filtered and concentrated in vacuo to afford a brown oil. The crude oil residue was purified on silica gel (hexanes / EtOAc, 3: 2) to afford the desired product (986 mg, 75%) as a white solid.
[389] 2- S -amino-1- [2- (3 -azidopropyl ) -4- R- (naphthalen-2-ylmethoxy) -pyrrolidin-1-yl] -3-phenylpropan-1-one ( 9) Preparation: 2- S - N- ( tert -butoxycarbonyl) -amino-1- [2- (3-azidopropyl) -4- R- (naphthalen-2-ylmethoxy) -pyrroli In a round bottom flask filled with din-1-yl] -3-phenylpropan-1-one, 8 , (986 mg, 1.77 mmol), TFA: CH ₂ Cl ₂ : H ₂ 0 (1: 1: 0.1, 10 ml) was added and the reaction mixture was stirred at rt for 1.0 h. The solution was concentrated to give the trifluoroacetic acid salt of the desired compound (1.0 g, 99%) as a clear oil, which was pure enough to be used for the next reaction without purification.
[390] 2- S -Acetylamino- N -{2- [2- S -(3-azidopropyl) -4- R -(Naphthalen-2-ylmethoxy) pyrrolidin-1-yl] -1- R Preparation of -Benzyl-2-oxo-ethyl} -3- (4-hydroxyphenyl) propionamide (10):
[391] 2- S -amino-1- [2- (3-azidopropyl) -4- R- (naphthalen-2-ylmethoxy) -pyrrolidin-1-yl] -3-phenyl in DMF (8.8 mL) Propane-1-one, 9 , (1.5 g, 2.63 mmol), N -acetyl- L -tyrosine (586 mg, 2.63 mmol), 1-hydroxybenzotriazole (709 mg, 5.25 mmol) and N -methylmor 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (564 mg, 3.15 mmol) was added to a solution of Pauline (0.9 mL, 7.88 mmol), and the reaction mixture was stirred at room temperature for 1 hour. . The reaction was quenched with saturated aqueous NH ₄ Cl and extracted twice with EtOAc (75 mL). The combined organic layers were washed with H ₂ 0 (80 mL), brine (80 mL), dried over Na ₂ SO ₄ , filtered and concentrated in vacuo to afford an oil. The crude oil was purified on silica gel (acetone / CH ₂ Cl ₂ , 3: 2) to afford the desired compound (1.03 mg, 60%) as a white solid.
[392] 2- S-acetylamino-N - {2- [S 2- - (3- aminopropyl) -4- R - (naphthalen-2-ylmethoxy) pyrrolidin-1-yl] -1-R- Preparation of Benzyl-2-oxo-ethyl} -3- (4-hydroxyphenyl) propionamide (11): 2- S -acetylamino- N- {2- [2- S- (in methanol (5.0 mL)) 3-azido-propyl) -4- R- (naphthalen-2-ylmethoxy) pyrrolidin-1-yl] -1- R -benzyl-2-oxo-ethyl} -3- (4-hydroxy- A solution of phenyl) -propionamide, 10 , (1.03 g, 1.56 mmol) and pyridine (0.07 mL, 0.78 mmol) was purged with argon and 10% by weight of palladium on carbon (500 mg) was added. The reaction mixture was stirred for 5 hours under hydrogen atmosphere. The reaction was then filtered through a pad of celite to remove the catalyst and the filtrate was concentrated in vacuo to give an embodiment of the invention (871 mg, 88%) as a white solid.
[393] This method can be used to prepare 3-aminopropyl analogs that represent one repeat of a pyrrolidinyl scaffold. The material obtained at this point was pure enough to be used directly for the preparation of the guanidino-pyrrolidine analogs of the present invention.
[394] Example 2
[395] 2- S -Acetylamino- N -{2- [2- S -(3-guanidinopropyl) -4- R -(Naphthalen-2-ylmethoxy) -pyrrolidin-1-yl] -1- R -Benzyl-2-oxo-ethyl] -3- (4-hydroxyphenyl) propionamide (13)
[396] 2- S - acetylamino - N - {1- R - benzyl -2- [2- S - (3- N , N '- bis (tert - butoxycarbonyl) guanidino propyl) -4- R - Preparation of (naphthalen-2-ylmethoxy) -pyrrolidin-1-yl] -2-oxo-ethyl} -3- (4-hydroxyphenyl) -propionamide (12): mercury chloride (II) (113 mg, 0.24 mmol) 2- S -acetylamino- N- {2- [2- S- (3-aminopropyl) -4- R- (naphthalen-2-ylmethoxy) pi in dry DMF (2 mL) Ralidin-1-yl] -1- R -benzyl-2-oxo-ethyl} -3- (4-hydroxyphenyl) propionamide, 11 , (125 mg, 0.20 mmol), 1,3-bis ( tert -Butoxycarbonyl) -2-methyl thiosudodourea (57 mg, 0.2 mmol) and triethylamine (0.1 mL, 0.59 mmol) were added and the reaction mixture was stirred at 0 ° C for 1 h. The reaction mixture was then diluted with EtOAc, filtered through a pad of celite and the filtrate was concentrated in vacuo to afford the crude product as an oil. The crude isolate was purified on silica gel (CH ₂ Cl ₂ / methanol, 14: 1) to afford the desired product (170 mg, 98%) as a white solid.
[397] 2- S -acetylamino- N- {1- R -benzyl-2- [2- S- (3-guanidinopropyl) -4- R- (naphthalen-2-ylmethoxy) pyrrolidine-1- Preparation of Il] -2-oxo-ethyl] -3- (4-hydroxyphenyl) propionamide (13): A solution of TFA: CH ₂ Cl ₂ : anisole (40: 55: 5, 3.0 mL) S -acetylamino- N- {1- R -benzyl-2- [2- S- (3- N, N' -bis ( tert -butoxycarbonyl) guanidinopropyl) -4- R- ( In a round bottom flask filled with naphthalen-2-ylmethoxy) pyrrolidin-1-yl] -2-oxo-ethyl] -3- (4-hydroxyphenyl) propionamide, 12 , (170 mg, 0.19 mmol) Was added and the reaction mixture was stirred for 3.25 h. The reaction mixture was then diluted with dichloroethane and concentrated in vacuo. The crude product was purified by reverse phase preparative HPLC to give the 50th embodiment of Table I (57 mg, 44%) as a white powder.
[398] Another category of receptor ligand analogs according to the invention relates to conformationally restricted rings containing a piperidine scaffold having the formula:
[399] ,
[400] In the formula, each carbon indicated by an asterisk may have any atomic arrangement. Table II relates to non-limiting examples of analogs containing the first aspect of this category, which analogs have the formula:
[401] ,
[402] In the formula, R, R ² , R ³ and R ⁹ are defined in Table II.
[403]
[404]
[405] The following is an overview of the synthetic route to prepare analogs 61-120, but other embodiments of piperidine scaffolds can be made by modifying this general method.
[406]
[407] Reagents and Conditions:
[408] (a) CbzCl, O ° C .; CH ₂ = CHCH ₂ MgCl, −78 ° C. to O ° C .;
[409] (b) Zn / HOAc.
[410]
[411] R ⁹ = phenyl for compound 1-28 and R ⁹ = 2-naphthyl for 29-60.
[412] Reagents and Conditions:
[413] (c) K-selectride, 10 ° C .;
[414] (d) NaH, PhCH ₂ Br (cpds 1-28), NaphCH ₂ Br (analogue 89-120), 0 ° C. to room temperature.
[415]
[416] Reagents and Conditions:
[417] (e) BH ₃ -THF, H ₂ O ₂ / NaOH, 0 ° C. to room temperature.
[418]
[419] Reagents and Conditions:
[420] (f) (BocNH) ₂ C═NH, diisopropyl azodicarboxylate Ph ₃ P, 0 ° C. to room temperature.
[421]
[422] Reagents and Conditions:
[423] (g) H ₂ , Pd / C, pyridine, room temperature.
[424]
[425] Reagents and Conditions:
[426] (h) Fmoc-D-phenylalanine (analogue 61, 65, 69, 73, 77, 71, 85, 89, 93, 97, 101, 105, 109, 113 and 57), Fmoc-D- (4-chloro) Phenylalanine (analogs 62, 66, 70, 74, 78, 82, 86, 90, 94, 98, 102, 106, 110, 114, and 118), Fmoc-D- (4-fluoro) phenylalanine (analog 63, 67, 71, 75, 79, 83, 87, 91, 95, 99, 103, 107, 111, 115 and 119), Fmoc-D- (3,4-difluoro) phenylalanine (analogue 64, 68, 72 , 76, 80, 84, 88, 92, 96, 100, 104, 108, 112, 116 and 120), ( i -propyl) ₂ NEt, PyBroP, -20 ° C.
[427]
[428] Reagents and Conditions:
[429] (i) piperidine, room temperature.
[430]
[431] Reagents and Conditions:
[432] (j) EDCI, HOBt, N -acetyl-L-phenylalanine (analogs 61-64, 89-92, and 117-120), N -acetyl- (2-imidazolinyl) -L-histidine (analog 65- 68 and 93-96), N -acetyl-L-histidine (analogs 69-72 and 97-100), N -acetyl-L- (4-fluoro) phenylalanine (analogs 73-76 and 101-104), N -Acetyl-L-tyrosine (analogs 77-80 and 105-108), N -acetyl-L- (4-chloro) phenylalanine (cpds 81-84 and 109-112), N -acetyl-L- (4-acetyl Tyrosine (analogues 85-88 and 113-116).
[433]
[434] Reagents and Conditions: (k) TFA, room temperature.
[435] Process for preparing piperidine synthetic intermediate
[436] The following is a process for preparing the pyrrolidine scaffold intermediate having the formula:
[437]
[438] In this example, R ⁹ is a 2-naphthyl moiety.
[439] N, N ' -D- tert Butoxycarbonyl N " -{3- S -[4- R -(Naphthalen-2-ylmethoxy) piperidin-2-yl] propyl} guanidine (20)
[440] Preparation of N-Cbz-allyl-2,3-dihydro-1 H -pyridin-4-one (14): benzyl chloroformate in 4-methoxypyridine (50 mL, 0.492 mol) in toluene (1 L) (70.3 mL, 0.492 mol) was added at 0 ° C. The resulting mixture was stirred at 0 ° C for 30 min, then cooled to -75 ° C and allyl magnesium chloride (295.5 mL, 0.591 mol) was added. The solution was kept at -75 ° C for 4 h and allowed to warm to 0 ° C, at which temperature a solution of 20% HCl was added to quench the reaction. The organic layer was isolated and purified on silica gel to give the desired product.
[441] Preparation of N-Cbz-2- S -allylpiperidin- 4-one (15): N-Cbz-6-allyl-2,3-dihydro-1 H -pyridine-4- in HOAc (238 mL) Zinc powder was added to a warm, 14 , (34.2 g, 0.126 mole) solution at room temperature. The solution was refluxed for 30 minutes, cooled to room temperature and this solid was removed by filtration through celite. The product was isolated by operation on neutral product.
[442] Preparation of N- Cbz-2- S -allyl-4- R -hydroxypiperidine (16): N- Cbz-2- S -allylpiperidin-4-one in THF (700 mL), 15 , To a solution of (34.2 g, 0.125 mol) K-selectide (135 mL, 0.150 mol) was added at 10 ° C. After 5 minutes, the reaction was quenched with water (60 mL). Operation on the neutral product was carried out to obtain the desired material which was purified on silica gel.
[443] Preparation of N- Cbz-2- S -allyl-4- R- (naphthalen-2-ylmethoxy) piperidine (17): N- Cbz-2- S -allyl-4- R in DMF (300 mL) To a solution of hydroxypiperidine, 16 , (22.11 g, 0.08 mol) 60% NaH (4.2 g, 0.103 mol) was added at 0 ° C. After stirring for 30 minutes, 2- (bromomethyl) -naphthalene (21.3 g, 0.096 mol) is added and the reaction is stirred at room temperature for 24 hours, after which the reaction is cooled to 0 ° C. and water is added. By quenching. Purification on silica gel after operation on the neutral product gave the desired product.
[444] Preparation of N- Cbz-2- S- (3-hydroxy) propyl-4- R- (naphthalen-2-ylmethoxy) piperidine (18): N- Cbz-2- S in THF (39 mL) To a solution of -allyl-4- R- (naphthalen-2-ylmethoxy) piperidine, 17 , (1.59 g, 3.83 mmol) was added borane / THF (4.2 mL, 4.221 mmol) at 0 ° C. and the reaction Allow to warm at room temperature for 30 minutes. The reaction was quenched with water then 3M NaOH (2.4 mL) and then quenched with 30% hydrogen peroxide (2.4 mL). Purification on silica gel after operation on the neutral product gave the desired product.
[445] N, N' -di- tert -butoxycarbonyl- N " -[3- S- [4- R- (naphthalen-2-ylmethoxy) -N- Cbz-piperidin-2-yl] propyl] Preparation of Guanidine (19): N- Boc- S- (3-hydroxy) propyl-4- R- (naphthalen-2-ylmethoxy) -piperidine (4.96 g, 11.89 mmol) in THF, triphenylforce To a solution of pin (3.74 g, 14.26 mmol), and 1,3-bis ( tert -butoxycarbonyl) guanidine (3.7 g, 14.27 mmol) was added diisopropyl azodicarboxylate (2.81 mL, 14.27 mmol). It was added at a temperature below 3 ° C. The solution was allowed to warm to room temperature, quenched by addition of water and purified on silica gel after operation on neutral product to give the desired product.
[446]
[447] N, N' -di- tert -butoxycarbonyl- N " -[3- S- [4-R- (naphthalen-2-ylmethoxy) piperidin-2-yl] propyl] guanidine (20) Preparation: N, N' -di- tert -butoxycarbonyl- N " -[3- S- [4- R- (naphthalen-2-yl-methoxy) -N- Cbz- in methanol (120 mL) A suspension of piperidin-2-yl] propyl] guanidine, 19 , (9.05 g, 13.43 mmol), pyridine (1.06 gm, 13.42 mmol) and 10% Pd / C (4.5 g) was hydrogenated at room temperature. This solid was removed by filtration and the resulting residue after concentration was purified on silica gel to afford the desired product.
[448] Piperidine synthetic intermediates having the formula:
[449] ,
[450] Can be prepared by substituting benzyl bromide with 2- (bromomethyl) naphthalene under the conditions as described above for the preparation of compound 17 .
[451] Example 3
[452] 2-acetylamino- N -{1- (4-Fluorobenzyl) -2- [2- (3-guanidinopropyl) -4- (naphthalen-2-ylmethoxy) piperidin-1-yl] -2-oxo-ethyl } -3- (4-hydroxyphenyl) propionamide (24)
[453] [2- [2- [3- ( N ', N " -di- tert -butoxycarbonylguanidino) propyl] -4-naphthylene-2-ylmethoxy) piperidin-yl] -1- (4-fluorobenzyl) -2-oxo-ethyl] -carbamic acid 9 H-fluoren-9-one Preparation of the methyl ester (21): N, N 'in dichloromethane - di - tert - butoxycarbonyl - N " -[3- S- [4- R- (naphthalen-2-yl-methoxy) piperidin-2-yl] propyl] guanidine, 20 , (0.41 g, 0.759 mmol), N -Fmoc- ( To a solution of 4-fluoro) phenylalanine (0.339 g, 0.836 mmol), and diisopropylethylamine (0.529 mL, 3.036 mmol) was added PyBroP (0.707 g, 1.517 mmol) at -20 ° C. This solution was kept at -20 [deg.] C. for 24 hours, after which the solvent was removed in vacuo and the resulting residue was purified on silica gel to give the desired product.
[454] N, N' -di- tert -butoxycarbonyl- N " -{3- [1- [2-amino-3- (4-fluorophenyl) propionyl] -4- (naphthylene-2-ylme Preparation of methoxy) piperidin-2-yl] propyl} guanidine (22): [2- [2- [3- ( N ', N " -di- tert -butoxycarbonylguanidino) in dichloromethane propyl] -4-naphthylene-2-ylmethoxy) piperidin-1-yl] -1- (4-fluoro) -oxo-ethyl] -carbamic acid 9 H-fluoren-9-yl-methyl ester A solution of, 21, (0.122 g, 0.132 mmol) and piperidine (0.25 mL) was stirred at room temperature for 30 minutes. Concentration in vacuo afforded the crude product, which was purified on silica gel.
[455] 2-acetylamino- N- [2- [2- [3- N ', N " -di- tert -butoxycarbonylguanidino) propyl] -4- (naphthylene-2-ylmethoxy) -pi Preparation of Ferridin-1-yl] -1- (4-fluorobenzyl) -2-oxoethyl] -3- (4-hydroxyphenyl) propionamide (23): N, N in DMF (2 mL) ' -Di - tert -butoxycarbonyl-N "-{3- [1- [2-amino-3- (4-fluorophenyl) propionyl] -4- (naphthylene-2-ylmethoxy) pi Solution of ferridin-2-yl] propyl} guanidine, 22 , (77 mg, 0.109 mmol), N -acetyl tyrosine (29.3 mg, 0.131 mmol) and 1-hydroxy-benzotriazole (31 mg, 0.162 mmol) To 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride was added. The solution was stirred at 0 ° C. for 2 hours, then partitioned between ether and aqueous bicarbonate, the organic phase was dried, concentrated in vacuo and purified on silica gel to afford the desired product.
[456] 2-acetylamino- {1- (4-fluorobenzyl-2- [2-[(3-guanidino) propyl] -4- (naphthylene-2-ylmethoxy) piperidin-1-yl] Preparation of 2-oxoethyl} -3- (4-hydroxyphenyl) propionamide (24): 2-acetylamino- N- [2- [2- [3- N ', in dichloromethane (2 mL) , N " -di- tert -butoxycarbonylguanidino) propyl] -4- (naphthylene-2-ylmethoxy) -piperidin-1-yl] -1- (4-fluorobenzyl) -2 To a solution of oxoethyl] -3- (4-hydroxyphenyl) propionamide, 23 , (55 mg, 0.06 mmole) was added trifluoroacetic acid (0.3 mL) and the solution was stirred at room temperature for 7 hours. Concentration and purification on silica gel gave the analog 107 of Table II, which was the desired product.
[457] Another category of receptor ligand analogs according to the invention relates to conformationally restricted rings containing a 5-ketopiperazine scaffold having the formula:
[458] .
[459] In the formula, the carbons marked with an asterisk may have any atomic arrangement. Table III relates to non-limiting examples of analogs containing the first aspect of this category, which analogs have the formula:
[460]
[461] Wherein R, R ² , R ³ , R ⁴ and R ⁹ are defined in Table III.
[462]
[463]
[464]
[465] The following is an overview of the synthetic route to prepare analogs 121-180, but other embodiments of the 5-ketopiperazine scaffold can be made by modifying this general method.
[466]
[467] Reagents and Conditions: (a) Acetic anhydride / pyridine, room temperature.
[468]
[469] Reagents and conditions: (b) O, N-dimethylhydroxylamine, HOBt, EDCI, N -methylmorpholine, DMF, O ° C.
[470]
[471] Reagents and conditions: (c) LAH, THF, -60 ° C.
[472]
[473] Reagents and Conditions: (d) NaBH (OAC) ₃ , DMF, 0 ° C. to room temperature.
[474]
[475] Reagents and Conditions: (e) CICH ₂ COCl, Et ₃ N, CH ₂ Cl ₂ , 0 ° C. to room temperature.
[476]
[477] Reagents and Conditions: (f) TFA / CH ₂ Cl ₂ , room temperature.
[478]
[479] Reagents and conditions: (g) Pyridine, CH ₂ Cl ₂ , room temperature.
[480]
[481] Reagents and conditions: (h) N- Boc-amino acids, EDCI, HOBt, DMF.
[482]
[483] Reagents and Conditions: (i) TFA / CH ₂ Cl ₂ , room temperature.
[484]
[485] Reagents and conditions: (j) N -acetyl-amino acid, EDCI, HOBt, DMF.
[486]
[487] Reagents and conditions: (k) H ₂ , PtO ₂ , MeOH.
[488] Preparation of 5-ketopiperazine Intermediates
[489] The following is a process for preparing 5-ketopiperazine intermediates having the formula:
[490] .
[491] In this example, R ⁹ is a 2-naphthylmethyl moiety.
[492] 3- S -[4- (2-naphthalen-2-ylethyl) -5-oxo-piperazin-2-yl] propionitrile (31)
[493] Preparation of 2- N- ( tert -butoxycarbonyl) amino-4-cyanobutanoic acid (25): Flask was placed in N - tert -butoxycarbonyl glutamine (24.6 g, 100 mmol), acetic anhydride (112 g, 110 mmol) and pyridine (180 mL). The mixture was stirred for 18 hours and then concentrated in vacuo. The residue was partitioned between EtOAc and water and the organic layer was washed several times with citric acid solution, then saturated NaCl. The organic phase was dried and concentrated in vacuo to afford the desired product, which was used without further purification.
[494] Preparation of 3-cyano-1- (methoxymethylcarbamoyl) propyl] carbamic acid tert -butyl ester (26): 2- N- ( tert -butoxycarbonyl) amino-4 in DMF (150 ml) Cyanobutanoic acid, 25 , (22.8 g, 100 mmol), O, N-dimethoxy-hydroxylamine hydrochloride (10.6 g, 110 mmol), hydroxybenzotriazole (16.2 g, 120 mmol) and N − A solution of methylmorpholine (132 mL, 120 mmol) was cooled to 0 ° C. and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide (24.9 g, 130 mmol) was added slowly. The resulting mixture was stirred for 2 h at 0 ° C., allowed to warm to rt and stirred for a further 2 h. The reaction solution is diluted with water and the resulting solid is collected by filtration, redissolved in EtOAc, extracted with water, dried and concentrated in vacuo to afford a residue, which is triturated with diethyl ether / hexanes and filtered Collected by gave a white solid. This product was pure enough for use without further purification.
[495] Preparation of 2- S - N- Boc-amino-4-cyanobutyraldehyde (27): 3-cyano-1- (methoxymethylcarbamoyl) propyl] carbamic acid tert -butyl ester in 500 mL of THF In a solution of, 26 , (27.1 g, 100 mmol) add LAH (100 mL of 1M solution in THF) at -30 ° C to -25 ° C for about 10 minutes, after which the reaction was cooled to -55 ° C, 3 Stirring was continued for hours. After cooling to -60 ° C, citric acid in methanol (1: 1 weight ratio) was added to quench the reaction. The temperature was maintained at about -45 ° C during quenching. The mixture was then allowed to warm to rt, partitioned between EtOAc and water and the aqueous phase was extracted again with EtOAc. The organic phases were combined, washed with saturated NaCl, dried and concentrated in vacuo to afford crude aldehyde which was used without further purification.
[496] Preparation of 3- S - N- Boc-amino-4- (2-naphthalen-2-ylethylamino) butylnitrile (28): Crude aldehyde 2- S - N- Boc-amino-4-cyanobutyraldehyde , 27 , was dissolved in DMF (200 mL) and a solution of 2-naphthylethyl amine (17.1 g, 100 mmol) in 125 mL of DMF was added. This solution was cooled to 0 ° C. and sodium triacetoxyhydride (42.4 g, 200 mmol) was added. The suspension was stirred at 0 ° C and allowed to warm to room temperature for 2 hours. A saturated aqueous solution of sodium bicarbonate was added until gas evolution ceased. This solution was extracted with diethyl ether, dried and concentrated to afford the crude product, which was purified on silica gel.
[497] Preparation of 3- S - N- Boc-amino-4-[(2-chloroacetyl-2-naphthalen-2-ylethyl) amino] -butylnitrile (29): Dichloromethane (500 mL) maintained at 0 ° C. To a solution of 3- S - N- Boc-amino-4- (2-naphthalen-2-ylethylamino) butylnitrile, 28 , (36.8 g, 100 mmol) and triethylamine (27.8 mL, 200 mmole) in Chloroacetyl chloride (14.7 g, 130 mmole) was added dropwise. The resulting solution was kept in an ice bath for an additional hour, the solution was concentrated in vacuo, and the crude material was purified on silica gel.
[498] Preparation of 3- S -amino-4-[(2-chloroacetyl-2-naphthalen-2-ylethyl) amino] butylnitrile (30): 3- S - N- Boc-amino-4-[(2- A solution of chloroacetyl-2-naphthalen-2-ylethyl) amino] butylnitrile, 29 , (44.4 g, 100 mmol), trifluoroacetic acid (50 mL), and dichloromethane (500 mL) was stirred at room temperature for 30 minutes. After stirring, the mixture was concentrated in vacuo. The crude product could be used without further purification.
[499] Preparation of 3- S- [4- (2-naphthalen-2-ylethyl) -5-oxo-piperazin-2-yl] propionitrile (31): 3- S -amino-4-[(2- Chloroacetyl-2-naphthalen-2-ylethyl) amino] -butylnitrile trifluoroacetic acid salt, 30 , (45.8 g, 100 mmol) was taken up in 1000 mL of dichloromethane and pyridine (50 mL) was added. The solution was stirred at rt for 24 h and then concentrated in vacuo. The resulting crude product was purified on silica gel to give the desired product as trifluoroacetic salt.
[500] Example 4
[501] 2-acetylamino- N -{2- [2- (3-Aminopropyl) -4- (2-naphthalen-2-ylethyl) -5-oxo-piperazin-1-yl] -1-benzyl-oxo-ethyl} -3- (4-hydroxyphenyl) propionamide (34)
[502] [2- [2- (2-cyanoethyl) -4- (2-naphthalen-2-ylethyl) -5-oxo-piperazin-1-yl] -1- (4-fluorobenzyl) -oxo Preparation of -ethyl] carbamic acid tert -butyl ester (32): 3- S- [4- (2-naphthalen-2-ylethyl) -5-oxo-piperazin-2-yl] in DMF (150 mL) Propionitrile trifluoroacetic acid salt, 31 , (42.1 g, 100 mmol), (R) -2- N- ( tert -butoxycarbonyl) amino-3- (4-fluorophenyl) propanoic acid (34.0 g, 120 mmol), a solution of 1-hydroxybenzotriazole (16.2 g, 120 mmol), and N -methylmorpholine (132 mL, 120 mmol) were cooled to 0 ° C. and 1- (3-dimethylamino Propyl) -3-ethylcarbodiimide (24.9 g, 130 mmol) was added slowly. The resulting mixture was stirred for 2 h at 0 ° C., then allowed to warm to room temperature and stirred. The reaction solution was diluted with water and the resulting solid collected by filtration, redissolved in EtOAc, extracted with water, dried and concentrated in vacuo to yield a white foaming residue.
[503] 3- [1- [2-amino-3- (4-fluorophenyl) propionyl] -4- (2-naphthalen-2-ylethyl) -5 - oxo-piperazin-2-yl] -propio Preparation of the nitrile (33): [2- [2-2-cyanoethyl) -4- (2-naphthalen-2-ylethyl) -5-oxo-piperazin-1-yl] -1- (4- A solution of fluorobenzyl) -2-oxo-ethyl] carbamic acid tert -butyl ester, 32 , (57.2 g, 100 mmol), trifluoroacetic acid (50 mL), and dichloromethane (500 mL) was added at room temperature. After stirring for an hour it was concentrated in vacuo. The crude product was dissolved in dichloromethane, the organic layer was washed with saturated sodium bicarbonate and concentrated in vacuo. The desired product was obtained in 94% yield.
[504] 2-acetylamino- N- [2- [2- (2-cyanoethyl) -4- (2-naphthalen-2-ylethyl) -5-oxo-piperazin-1-yl] -1- (4 Preparation of -Fluorobenzyl) -2-oxo-ethyl] -3- (4-hydroxyphenyl) -propionamide (34): 3- [1- [2-amino-3- () in DMF (150 mL) 4-fluorophenyl) propionyl] -4- (2-naphthalen-2-ylethyl) -5-oxo-piperazin-2-yl] propionitrile, 33 , (47.2 g, 100 mmol), N − A solution of acetyl-L-tyrosine (22.3 g, 120 mmol), 1-hydroxybenzotriazole (16.2 g, 120 mmol), and N-methylmorpholine (132 mL, 120 mmol) is cooled to 0 ° C, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide (24.9 g, 130 mmol) was added slowly. The reaction mixture was added at 0 ° C. for 2 hours, then allowed to warm to room temperature and stirred for an additional 2 hours. The reaction solution was diluted with water and the resulting solid collected by filtration, redissolved in EtOAc, extracted with water, dried and concentrated in vacuo to afford the crude product which was purified on silica gel.
[505] 2-acetylamino- N- [2- [2- (3-aminoethyl) -4- (2-naphthalen-2-ylethyl) -5-oxo-piperazin-1-yl] -1- (4- Preparation of Fluorobenzyl) -2-oxo-ethyl] -3- (4-hydroxyphenyl) -propionamide (35): 2-acetylamino- N- [2- [2- (in methanol (3 mL)) 2-cyanoethyl) -4- (2-naphthalen-2-ylethyl) -5-oxo-piperazin-1-yl] -1- (4-fluorobenzyl) -2-oxo-ethyl] -3 A drop of concentrated HCl was added to a suspension of-(4-hydroxyphenyl) -propionamide, 34 , (57 mg) and PtO ₂ (11 mg at 20% by weight). This solution was hydrogenated at 45 psi for 1.5 hours. The catalyst was removed by filtration and the filtrate was concentrated in vacuo to afford the final product, which was purified by preparative HPLC using acetonitrile: TFA: water to give 26 mg. This corresponds to analog 167 in Table III.
[506] Another aspect of this category of receptor ligand analogs relates to conformationally restricted rings containing a 5-ketopiperazine scaffold having the formula:
[507] .
[508] In the formula, the Y unit contains a guanidino moiety. Table III relates to non-limiting examples of analogs containing the first aspect of this category, which analogs have the formula:
[509] .
[510] Wherein R, R ² , R ³ , R ⁴ and R ⁹ are defined in Table IV.
[511]
[512]
[513]
[514] The following is an overview of the synthetic route for the preparation of analogs 181-240, starting with synthetic intermediates which may be prepared in a similar manner to the compounds described in Example 3, analog 167 above.
[515]
[516] Reagents and Conditions: (a) BocNHC (SCH ₃ ) = NBoc, HgCl ₂ , room temperature.
[517]
[518] Reagents and Conditions: (b) TFA: CH ₂ Cl ₂ , room temperature.
[519] Example 5
[520] 2-acetylamino- N -[2- [2- (3-guanidinopropyl) -4- (2-naphthalen-2-ylethyl) -5-oxo-piperazin-1-yl] -1- (fluorobenzyl) -2 -Oxo-ethyl] -3- (4-hydroxyphenyl) -propionamide (37)
[521] 2-acetylamino- N- [2- [2- [3- ( N ', N " -di-Boc-guanidino) propyl] -4- (2-naphthalen-2-ylethyl) -5-oxo Preparation of -piperazin-1-yl] -1- (4-fluorobenzyl) -2-oxo-ethyl] -3- (4-hydroxyphenyl) propionamide (36): mercury chloride (II) (10.3 mg, 0.038 mmol) was diluted with 2-acetylamino- N- [2- [2- (3-aminoethyl) -4- (2-naphthalen-2-ylethyl) -5-oxo- in dry DMF (2.0 mL). Piperazin-1-yl] -1- (4-fluorobenzyl) -2-oxo-ethyl] -3- (4-hydroxyphenyl) propionamide, 35 , (26 mg, 0.038 mmol), 1 To a solution of, 3-bis ( tert -butoxycarbonyl) -2-methyl-2-thiosudo urea (11 mg, 0.038 mmol) and triethylamine (21 mL, 0.152 mmol) was added and the reaction mixture was added. The reaction mixture was then stirred for 1 h at 0 ° C. The reaction mixture was then diluted with EtOAc, filtered through a pad of celite and the filtrate was concentrated in vacuo to afford the crude product as an oil. Prize Purification in (CH ₂ Cl ₂ / methanol, 14: 1) gave 35 mg of the desired product as a white solid.
[522] 2-acetylamino- N- [2- [2- (3-guanidinopropyl) -4- (2-naphthalen-2-ylethyl) -5-oxo-piperazin-1-yl] -1- ( Preparation of 4-fluorobenzyl) -2-oxo-ethyl] -3- (4-hydroxyphenyl) -propionamide (37): 2-acetylamino- N- [2- [2- [3- ( N ', N " -di-Boc-guanidino) propyl] -4- (2-naphthalen-2-ylethyl) -5-oxo-piperazin-1-yl] -1- (4-fluorobenzyl) 2-oxo-ethyl] -3- (4-hydroxyphenyl) -propionamide, 36 , (35 mg, 38 mmol), trifluoroacetic acid (1 mL) and dichloromethane (2 mL) at room temperature The solution was concentrated in vacuo and the crude product was purified on silica gel (acetonitrile: TFA: water) to give 24 mg (86% yield) of the final product, which corresponds to analog 227 in Table IV. It was.
[523] Another category of receptor ligand analogs according to the invention relates to conformationally restricted rings containing a 3-keto-piperazine scaffold having the formula:
[524] .
[525] In the formula, the carbon indicated by the asterisk may have any atomic arrangement. Table V relates to non-limiting examples of analogs containing the first aspect of this category, which analogs have the formula:
[526] .
[527] In the formula, R, R ² , R ³ , R ⁴ , and R ⁹ are defined in Table V.
[528]
[529]
[530] The following is an overview of the synthetic route for the preparation of analogs 241-300, but other embodiments of piperazine scaffolds can be made by modifying this general method.
[531]
[532] Reagents and Conditions: (a) EDCI, HOBt, DMF.
[533]
[534] Reagents and Conditions: (b) TFA: CH ₂ Cl ₂ : H ₂ 0, room temperature; (c) 2-nitrosulfonyl chloride, TEA, CH ₂ Cl ₂ , 0 ° C. to room temperature.
[535]
[536] Reagents and Conditions: (d) BrCH ₇ CH ₂ Br, K ₂ CO ₃ , DMF; 55 ° C.
[537]
[538] Reagents and Conditions: (e) p-thiophenol, K ₂ CO ₃ , acetonitrile; Room temperature.
[539]
[540] Reagents and Conditions: (f) EDCI, HOBt, DMF.
[541]
[542] Reagents and conditions: (g) H ₂ : PtO ₂ , MeOH.
[543] Preparation of 3-ketopiperazine Intermediates
[544] The following is a process for preparing 5-ketopiperazine intermediates having the formula:
[545] .
[546] In this example, R ⁹ is a 2-naphthyl moiety.
[547] 2- [3- (3-Benzyloxycarbonylaminopropyl) -2-oxo-piperazin-1-yl] -3-naphthalen-2-yl-propionic acid methyl ester (42)
[548] Preparation of 2- (5- N- Cbz-amino-2- N- Boc-amino-pentanoylamino) -3-naphthalen-2-yl-propionic acid methyl ester (38): 1-amino in DMF (150 mL) 3-naphthalen-2-yl propionic acid methyl ester (22.9 g, 100 mmol), 5-benzyloxycarbonylamino-2- tert -butoxycarbonylamino pentanic acid (33.6 g, 100 mmol), hydroxybenzotria A solution of sol (16.2 g, 120 mmol), and N-methylmorpholine (132 mL, 120 mmol) was cooled to 0 ° C. and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide (24.9 g , 13 mmol) was added slowly. The resulting mixture was stirred for 2 h at 0 ° C., then allowed to warm to rt for another 2 h and stirred. The reaction solution was diluted with water and the resulting solid collected by filtration, redissolved in EtOAc, extracted with water, dried and concentrated in vacuo to afford a residue, which was purified on silica gel.
[549] Preparation of 2- (2-amino-5- N- Cbz-aminopentanoylamino) -3-naphthalen-2-yl-propionic acid methyl ester (39): 2- (5- N- Cbz-amino-2- N -Boc-aminopentanoylamino) -3-naphthalen-2-yl-propionic acid methyl ester, 38 , (6.0 g, 10.3 mmol) was added in 32 ml of a solution prepared from 2: 1: 0.1 parts of dichloromethane, TFA and water. Dissolved. The reaction mixture was stirred for 3 hours. The solvent was removed in vacuo and the residue was treated with 1,2-dichloromethane and this was removed in vacuo. This was repeated several times to give 9.84 g of crude residue which was used for the next step without further purification.
[550] Preparation of 2- [5- N- Cbz-amino-2- (2-nitro-benzenesulfonylamino) pentanoylamino] -3-naphthalen-2-yl propionic acid methyl ester (40): 2- (2-amino -5- N- Cbz-aminopentanoylamino) -3-naphthalen-2-yl-propionic acid methyl ester, 39 , is dissolved in dichloromethane (200 ml), triethylamine (0.5 ml) and the solution are iced. Cooled in bath. o -nitrosulfonyl chloride (4.5 g, 20.6 mmol) was added and cooling for 1 h, then stirring was continued at rt for 6 h. The reaction mixture was treated with 1M citric acid and the solution was extracted with ethyl acetate. The organic layer was washed with saturated aqueous solution of sodium carbonate and water. The crude material was purified on silica (1: 2 hexanes / ethyl acetate) to afford the desired product (3.6 g).
[551] 2- [3- (3-benzyloxycarbonylaminopropyl) -4- (2-nitro-benzenesulfonyl) -2-oxo-piperazin-1-yl] -3-naphthalen-2-yl-propionate methyl Preparation of the ester (41): 2- [5-benzyloxycarbonylamino-2- (2-nitro-benzenesulfonylamino) -pentanoylamino] -3-naphthalen-2-yl- in DMF (50 mL) A mixture of propionic acid methyl ester, 40 , (2.4 g, 3.63 mmol), dibromoethane (3.8 mL, 4.36 mmol) and potassium carbonate (5.0 g, 36.3 mmol) was stirred at 55 ° C for 18 h. The reaction mixture was cooled at room temperature, treated with 1M KHS0 ₄ and the resulting solution was extracted with ethyl acetate. The crude product was purified on silica to give 2.76 g of the desired product (EtOAc / hexane mixtures 1: 2, 1: 1, 100% EtOAc, then eluting with EtOAc with 5% MeOH).
[552] Preparation of 2- [3- (3- N -benzyloxycarbonylaminopropyl) -2-oxo-piperazin-1-yl] -3-naphthalen-2-yl-propionic acid methyl ester 42: acetonitrile ( 2- [3- (3-benzyloxycarbonyl-amino-propyl) -4- (2-nitro-benzenesulfonyl) -2-oxo-piperazin-1-yl] -3-naphthalene- in 10 ml) A mixture of 2-yl-propionic acid methyl ester, 41 , (1.9 g, 2.8 mmol), p-thiophenol (1.6 g, 12.4 mmol) and K ₂ CO ₃ (2.3 g, 16.6 mmol) is stirred at room temperature for 18 hours. It was. The reaction mixture was concentrated in vacuo and the resulting residue was treated with 1 M HCl (10 ml). The aqueous phase was extracted with EtOAc and purified on silica to give 2.58 g of the desired product (EtOAc / hexane mixtures 1: 1, 100% EtOAc, then eluting with EtOAc with 5% MeOH).
[553] 3-ketopiperazine intermediates having the formula:
[554] ,
[555] It can be prepared by substituting 1-amino-3-naphthalen-2-yl-propionic acid methyl ester with phenylalanine methyl ester in the synthesis of compound 38 described above.
[556] Example 6
[557] 2- [4- [2- [2-acetylamino-3- (4-hydroxyphenyl) -propionylamino] -3- (4-fluorophenyl) propionyl] -3- (3-aminopropyl) -2-oxo-piperazin-1-yl]- N -Methyl-3-naphthalen-2-yl-propionamide (44)
[558] 2- [4- [2 [2-acetylamino-3- (4-hydroxyphenyl) propionylamino] -3- (4-fluorophenyl) propionyl] -3- (3- N- Cbz-amino Propyl) -2-oxo-piperazin-1-yl] -3-naphthalen-2-yl-propionic acid methyl ester (43): 2- [3- (3- N- Cbz- in DMF (150 mL) Aminopropyl) -2-oxo-piperazin-1-yl] -3-naphthalen-2-yl-propionic acid methyl ester, 42 , (50.4 g, 100 mmol), 2- [2-acetylamino-3- (4 -Hydroxyphenyl) -propionylamino] -3- (4-fluorophenyl) propionic acid (38.8 g, 100 mmol), hydroxybenzotriazole (16.2 g, 120 mmol), and N-methylmorpholine (132 mL, 120 mmol) was cooled to 0 ° C. and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide (24.9 g, 130 mmol) d slowly added. The reaction mixture was stirred at 0 ° C. for 2 hours, then allowed to warm for another 2 hours at room temperature and stirred. The reaction solution was diluted with water and the resulting solid collected by filtration, redissolved in EtOAc, extracted with water, dried and concentrated in vacuo to afford a residue, which was purified on silica gel.
[559] 2- [4- [2- [2-acetylamino-3- (4-hydroxyphenyl) propionylamino] -3- (4-fluorophenyl) propionyl] -3- (3-aminopropyl)- Preparation of 2-oxo-piperazin-1-yl] -3-naphthalen-2-ylpropionic acid methyl ester (44): 2- [4- [2- [2-acetylamino-3- (4-hydroxyphenyl ) Propionylamino] -3- (4-fluorophenyl) propionyl] -3- (3- N- Cbz-aminopropyl) -2-oxo-piperazin-1-yl] -3-naphthalene-2- A solution of mono-propionic acid methyl ester, 43 , (8.74 g, 10 mmol) was suspended in methanol (100 ml) and hydrogenated at 40 psi in the presence of 10% Pd / C for 16 hours. The solution was filtered to remove the catalyst and the crude product was purified by preparative HPLC using a linear gradient of acetonitrile in water with 0.1% TFA to afford the desired product corresponding to analog 287 in Table V.
[560] Another iteration of receptor ligand analogs of this category relates to analogs having the formula:
[561]
[562] In the formula, R, R ² , R ⁴ and R ⁹ are listed in Table VI.
[563]
[564]
[565]
[566] The following is an overview of the synthetic route for the preparation of analogs 301-360, but other embodiments of the 3-ketopiperazine scaffold can be made by modifying this general method.
[567]
[568] Reagents and Conditions: (h) BocNHC (SCH ₃ ) = NBoc, HgCl ₂ , room temperature.
[569]
[570] Reagents and Conditions: (i) TFA: CH ₂ Cl ₂ , room temperature;
[571] Example 7
[572] 2- [4- [2- [2-acetylamino-3- (4-hydroxyphenyl) propionylamino] -3- (4-fluorophenyl) propionyl] -3- (3-guanidinopropyl ) -2-oxo-piperazin-1-yl-propionic acid methyl ester (46)
[573] 2- [4- [2- [2-acetylamino-3- (4-hydroxyphenyl) propionylamino] -3- (4-fluorophenyl) propionyl] -3- (3- N, N ' Preparation of -bis ( tert -butoxycarbonyl) guanidinopropyl) -2-oxo-piperazin-1-yl-propionic acid methyl ester (45): dry mercury chloride (II) (5.7 g, 12 mmol) 2- [4- [2- [2-acetylamino-3- (4-hydroxyphenyl) propionylamino] -3- (4-fluorophenyl) propionyl] -3- (in DMF (100.0 mL) 3-Aminopropyl) -2-oxo-piperazin-1-yll-3-naphthalen-2-yl-propionic acid methyl ester, 44 , (7.4, 10 mmol), 1,3-bis ( tert -butoxycar To a solution of bonyl) -2-methyl-2-thiosudo urea (2.9 g, 10 mmol) and triethylamine (4.2 mL, 30 mmol) was added and the reaction mixture was stirred at 0 ° C for 1.0 h. The reaction mixture was diluted with EtOAc, then filtered through a pad of celite and the filtrate was concentrated in vacuo to afford the crude product. The crude isolate was purified on silica gel (CH ₂ Cl ₂ / methanol, 14: 1) to afford the desired product.
[574] 2- [4- [2- [2-acetylamino-3- (4-hydroxyphenyl) propionylamino] -3- (4-fluorophenyl) propionyl] -3- (3-guanidinopropyl ) -2-oxo-piperazin-1-yl-propionic acid methyl ester (46): 2- [4- [2- [2-acetylamino-3- (4-hydroxyphenyl) propionylamino]- 3- (4-fluorophenyl) propionyl] -3- (3- N, N' -bis ( tert -butoxycarbonyl) guanidinopropyl) -2-oxo-piperazin-1-yl-propionic acid Methyl ester, 45 , (10.4 g, 10 mmol), trifluoroacetic acid (5 mL) and dichloromethane (50 mL) were stirred at rt for 2 h and then concentrated in vacuo. The crude product was dissolved in dichloromethane and the organic layer was washed with saturated sodium bicarbonate, dried and concentrated in vacuo to afford the desired product.
[575] Another iteration of this category relates to analogues in which R ¹⁰ is a -CONH ₂ unit, which provides a receptor ligand having the formula:
[576] .
[577] Wherein R, R ² , R ³ , R ⁴ , and R ⁹ are receptor ligands defined in Table VII or having the formula:
[578] .
[579] Wherein R, R ² , R ³ , R ⁴ , and R ⁹ are defined in Table VIII.
[580]
[581]
[582]
[583]
[584]
[585]
[586] The following is an overview of the synthetic route for the preparation of analogs 361-420. In the following method R ⁹ is 2-naphthylmethyl, but other embodiments of this piperazine scaffold can be prepared by modifying this general method. As an example, in the synthesis of compound 38, when ⁹ -amino-3-naphthalen-2-yl propionic acid is substituted with phenylalanine, R ⁹ is an analog that is benzyl.
[587]
[588] Reagents and conditions: (a) LiOH, 0 ° C.
[589]
[590] Reagents and Conditions: (b) NH ₂ CH ₃ , PyBOP, room temperature.
[591]
[592] Reagents and Conditions: (c) TFA / CH ₂ Cl ₂ , room temperature.
[593]
[594] Reagents and conditions: (d) HOBt, EDCI, N-methylmorpholine, DMF, 0 ° C.
[595]
[596] Reagents and Conditions: (e) H ₂ , 10% Pd / C; MeOH.
[597] Example 8
[598] 2-4- [2- [2-acetylamino-3- (4-hydroxyphenyl) propionylamino] -3- (4-fluorophenyl) propionyl] -3- (3-aminopropyl) -2 Oxo-piperazin-1-yl]- N -Methyl-3-naphthalen-2-yl-propionamide (51)
[599] 2- {3- ( N- Cbz-aminopropyl) -4- [2- N- Boc-amino-3- (4-fluorophenyl) -propionyl-2-oxo-piperazin-1-yl)- Preparation of 3-naphthalen-2-yl propionic acid (47): 2- [5- N- Cbz-amino-2- (2- N- Boc-amino) pentanoylamino] -3-naphthalene in THF (15 ml) The mixture of 2-yl-propionic acid methyl ester (0.755 g, 1 mmol) was cooled in an ice bath and treated with a solution of LiOH (0.12 g, 5 mmol) in water (7.5 ml). The solution was stirred at 0 ° C. for 1 hour and then allowed to warm to room temperature and stirred for an additional 3 hours. The reaction was then diluted with water (30 ml), cooled in an ice bath and acidified to pH 3-4 with 1M HCl. The resulting solution was extracted with EtOAc. The organic phase was dried and concentrated in vacuo to extract 0.58 g (75%) of the desired product.
[600] {3- [1- [2- N- Boc-amino (4-fluorophenyl) propionyl] -4- (1-methylcarbamoyl-2-naphthalen-2-ylethyl) -3-oxo-pipe Preparation of Razin-2 -yl] propyl} -carbamic acid benzyl ester 48: 2- {3- ( N- Cbz-aminopropyl) -4- [2- N- Boc-amino- in DMF (15 ml) 3- (4-Fluorophenyl) -propionyl-2-oxo-piperazin-1-yl) -3-naphthalen-2-yl propionic acid, 47 , (0.6 g, 0.77 mmol), 2 M methylamine (3 To the mixture of ml) was added benzotriazol-1-yl-oxy-tris-pyrrolidinol-phosphonium hexafluorophosphate (PyBOP) (0.6 g, 1.15 mmol). The solution was stirred for 18 hours, then diluted with water (80 ml) and the solution was extracted with EtOAc. The organic phase was dried and concentrated in vacuo and the resulting crude product was purified on silica gel to give 0.56 g of the desired product (EtOAc / hexane 1: 3, then 1: 1 and 10% methanol in EtOAc).
[601] {3- [1- [2-amino-3- (4-fluorophenyl) propionyl] -4- (1-methylcarbamoyl-2-naphthylene-2-ylethyl) -3-oxo-pipe Preparation of Razin-2 -yl] propyl} -carbamic acid benzyl ester (49): {3- [1- [2- N- Boc-amino-3- (4-fluorophenyl) propionyl] -4- ( 1-methylcarbamoyl-2-naphthalen-2-ylethyl) -3-oxo-piperazin-2-yl] propyl} -carbamic acid benzyl ester, 48 , trifluoroacetic acid (50 mL), and dichloromethane (500 mL) was stirred at rt for 2 h and then concentrated in vacuo. The crude product was dissolved in dichloromethane and the organic layer was washed with saturated sodium bicarbonate, dried and concentrated in vacuo to afford the desired product.
[602] {3- [1- [2- [2-acetylamino-2- (4-hydroxyphenyl) -2-acetylamino] -3- (4-fluorophenylpropionyl] -4- (1-methylcarr Preparation of Bamoyl-2-naphthylene-2-ylethyl) -3-oxo-piperazin-2-yl] propyl} -carbamic acid benzyl ester (50): {3- [1- in DMF (150 mL) [2-amino-3- (4-fluorophenyl) propionyl] -4- (1-methylcarbamoyl-2-naphthylene-2-ylethyl) -3-oxo-piperazin-2-yl] Propyl} -carbamic acid benzyl ester, 49 , (66.8 g, 100 mmol), N-acetyl-L-tyrosine (26.8 g, 120 mmol), 1-hydroxybenzotriazole (16.2 g, 120 mmol), and N -Methylmorpholine (132 mL, 120 mmol) was cooled to 0 ° C and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide (24.9 g, 130 mmol) was added slowly. The resulting mixture was 0 After stirring for 2 h at < RTI ID = 0.0 > C, < / RTI > Home, and re-dissolved in EtOAc, extracted with water, dried and concentrated in vacuo to give the desired compound.
[603] 2-4- [2- [2-acetylamino-3- (4-hydroxyphenyl) propionylamino] -3- (4-fluorophenyl) propionyl] -3- (3-aminopropyl) -2 -Oxo-piperazin-1-yl] -N -methyl-3-naphthalen-2-yl-propionamide (51): {3- [1- [2- [2-acetylamino-2- (4 -Hydroxyphenyl) -2-acetylamino] -3- (4-fluorophenylpropionyl] -4- (1-methylcarbamoyl-2-naphthylene-2-ylethyl) -oxo-piperazine- 2-yl] propyl} -carbamic acid benzyl ester, 50 , (8.59 g, 10 mmol) was suspended in methanol (100 ml) and hydrogenated in the presence of 10% Pd / C for 16 h at 40 psi. The catalyst was removed by filtration and the crude product was purified on preparative HPLC using a linear gradient of acetonitrile in water with 0.1% TFA to afford the receptor ligand analog 457, the desired product.
[604] Analogs 421-480, the receptor ligands of the invention illustrated in Table VIII, contain a guanidinopropyl moiety. These analogs can be suitably prepared by modifying the method described above to convert compound 35 to compound 37 .
[605] Another aspect of the invention relates to a 3-ketopiperazine receptor ligand having the formula:
[606]
[607] In the formula, R, R ² , R ⁴ , R ⁹ and R ¹⁷ are defined in Table IX below.
[608]
[609]
[610] The following outlines a synthetic route for the preparation of analog 481-536, but other embodiments of 3-ketopiperazine scaffolds in which R ¹⁷ is ethyl, propyl and the like can be prepared by modifying this general method.
[611]
[612] Reagents and Conditions (a): TBDMSCl, DMF; 0 ° C. to room temperature.
[613]
[614] Reagents and Conditions (b): 2-nitrobenzylsulfonyl chloride, K ₂ CO ₃ , DME, 0 ° C. to room temperature.
[615]
[616] Reagents and conditions: (c) HOBt, EDCI, N-methylmorpholine, DMF, O ° C.
[617]
[618] Reagents and Conditions: (d) BrCH ₂ CH ₂ Br, K ₂ CO ₃ , DMF; 55 ° C.
[619]
[620] Reagents and conditions: (e) LiOH, 0 ° C.
[621]
[622] Reagents and conditions: (f) NH ₂ CH ₃ , PyBOP, room temperature.
[623]
[624] Reagents and Conditions: (g) p-thiophenol, K ₂ CO ₃ , acetonitrile; Room temperature.
[625]
[626] Reagents and conditions: (h) (Boc) ₂ 0, TEA, DCM, room temperature.
[627]
[628] Reagents and conditions: (i) tetrabutylammonium fluoride, water, room temperature.
[629]
[630] Reagents and conditions: (j) Ac ₂ 0, pyridine, DMAP, DCM, room temperature.
[631]
[632] Reagents and conditions: (k) TFA, DCM, room temperature.
[633]
[634] Reagents and conditions: (l) HOBt, EDCI, N-methylmorpholine, DMF, 0 ° C.
[635]
[636] Reagents and conditions: (m) TFA, DCM, room temperature.
[637]
[638] Reagents and conditions: (n) HOBt, EDCI, N-methylmorpholine, DMF, 0 ° C.
[639] Preparation of 3-ketopiperazine Intermediates
[640] The following is a method for preparing 3-ketopiperazine intermediates having the formula:
[641]
[642] 2- {3- [2- (tert-Butyldimethylsilanyloxy) ethyl] -2-oxo-piperazin-1-yl} -N-methyl-3-naphthalen-2-yl-propionamide (58)
[643] Preparation of 2-amino-4- ( tert -butyldimethylsilanyloxy) butyric acid (52): imidazole (20.4 g, 300 mmol) was added to homoserine (11.9 g, 100 mmol) in DMF (100 mL) and After stirring this solution for 15 minutes, it cooled to 0 degreeC. tert -butyldimethylsilyl chloride (13.7 g, 91 mmol) was added and the mixture was stirred at 0 ° C. for 10 minutes and at room temperature for 4 hours. The reaction mixture was poured into water (3 L) and the resulting solid collected by filtration. The isolated product was dried and used without further purification.
[644] Preparation of 4- ( tert -butyldimethylsilanyloxy) -2- (2-nitrobenzenesulfonylamino) butyric acid (53): 2-amino-4- ( tert -butyldimethylsilanyloxy) butyric acid, 52 , ( 23.3 g, 10 mmol) is dissolved in a mixture of 1,2-dimethoxyethane (800 mL), water (800 mL) and K ₂ CO ₃ (20.7 g, 150 mmol), and the resulting solution is cooled to 0 ° C. It was. After 15 minutes, 2-nitrobenzylsulfonyl chloride (26.6 g, 120 mmol) was added, the cold bath was removed and the mixture was stirred for 18 hours. The reaction mixture was acidified to pH 3-4 with 1N HCl and the solution was extracted several times with EtOAc. The combined organic layers were dried and concentrated in vacuo and the crude product was purified on silica gel to give 19.3 g (46%) of the desired product.
[645] Preparation of 2- [4- ( tert -butyldimethylsilanyloxy) -2- (2-nitrobenzenesulfonylamino) butyrylamino] -3-naphthalen-2-yl propionic acid methyl ester (54): DMF (150 4- ( tert -butyldimethylsilanyloxy) -2- (2-nitrobenzenesulfonylamino) butyric acid, 53 , (41.9 g, 100 mmol), 2-amino-3-naphthalen-2-yl propionic acid in mL) Methyl ester (41.9 g, 100 mmol), 2-amino-3-naphthalen-2-yl propionic acid methyl ester (22.9 g, 100 mmol), hydroxybenzotriazole (16.2 g, 120 mmol), and N-methylmor A solution of Pauline (132 mL, 120 mmol) was cooled to 0 ° C. and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide (24.9 g, 130 mmol) was added slowly. The resulting mixture was stirred at 0 ° C. for 2 hours, then allowed to warm to room temperature for 2 hours and stirred. The reaction solution was diluted with water and the resulting solid collected by filtration, redissolved in EtOAc, extracted with water, dried and concentrated in vacuo to afford the crude product, which was purified on silica gel to give 34.7 g (55%). Obtained.
[646] 2- [3- [2- ( tert -butyldimethylsilanyloxy) ethyl] -4- (2-nitrobenzene-sulfonyl) -2-oxo-piperidin-1-yl] -3-naphthalene-2- Preparation of one propionic acid methyl ester 55: 2- [4- ( tert -butyldimethylsilanyloxy) -2- (2-nitrobenzenesulfonylamino) -butyrylamino] -3- in DMF (500 ml) A mixture of naphthalen-2-yl propionic acid methyl ester, 54 , (63 g, 100 mmol), 1,2-dibromoethane (10.3 mL, 120 mmol), potassium carbonate (138 g, 1 mol) was added at 55 ° C. Stir for 18 hours. The reaction mixture was cooled to room temperature, treated with 1M KHS0 ₄ and the resulting solution was extracted with ethyl acetate. The crude product was purified on silica (EtOAc / hexanes mixture 1: 2, 1: 1, 100% EtOAc, then eluted with EtOAc with 5% MeOH) to give 50.8 g (77%) of the desired product.
[647] 2- [3- [2- tert -butyldimethylsilanyloxy) ethyl] -4- (2-nitrobenzenesulfonyl) -2-oxo-piperazin-1-yl] -3-naphthalen-2-yl propionic acid Preparation of (56): 2- [3- [2- ( tert -butyldimethylsilanyloxy) ethyl] -4- (2-nitrobenzenesulfonyl) -oxo-piperizine-1- in THF (1000 mL) A mixture of il] -3-naphthalen-2-yl propionic acid methyl ester, 55 , (65.6 g, 100 mmol) was cooled in an ice bath and treated with LiOH (21 g, 500 mmol) in water (750 mL). The solution was stirred at 0 ° C. for 1 hour and then allowed to warm to room temperature for another 3 hours and stirred. The reaction was then diluted with water (3 L), cooled in an ice bath and acidified to pH 3-4 with 1M HCl. The resulting solution was extracted with EtOAc. The organic phase was dried and concentrated in vacuo to give 48.2 g (75%) of the desired product.
[648] 2- [3- [2- ( tert -butyldimethylsilanyloxy) ethyl] -4- (2-nitrobenzenesulfonyl) -2-oxo-piperazin-1-yl] -N -methyl-3-naphthalene Preparation of 2 -yl propionamide (57): 2- [3- [2- tert -butyldimethylsilanyloxy) ethyl] -4- (2-nitrobenzene-sulfonyl) -2 in DMF (200 mL) -Benzotriazol-1-yl-oxy in a mixture of oxo-piperazin-1-yl] -3-naphthalen-2-yl propionic acid, 56 , (6.4 g, 10 mmol), 2M methylamine (40 ml) -Tris-pyrrolidinol-phosphonium hexafluorophosphate (PyBOP) (7.8 g, 15 mmol) was added. The solution was stirred for 18 hours, then diluted with water (500 mL) and the solution was extracted with EtOAc. The organic phase was dried, concentrated in vacuo and the resulting crude product was purified on silica gel (EtOAc / hexane 1: 3, then 1: 1 and 10% methanol in EtOAc) to afford the desired product.
[649] 2- {3- [2- ( tert -butyldimethylsilanyloxy) ethyl] -2-oxo-piperazin-1-yl} -N -methyl-3-naphthalen-2-yl-propionamide (58) Preparation: 2- [3- [2- ( tert -butyldimethylsilanyloxy) ethyl] -4- (2-nitrobenzene-sulfonyl) -2-oxo-piperazin-1-yl] -N -methyl- A solution of 3-naphthalen-2-yl propionamide, 57 , (6.5 g, 10 mmol), trifluoroacetic acid (5 mL), and dichloromethane (50 mL) was stirred at room temperature for 2 hours and then concentrated in vacuo. The crude product was dissolved in dichloromethane and the organic layer was washed with saturated sodium bicarbonate, dried and concentrated in vacuo to afford the desired product.
[650] Example 9
[651] Acetic acid-2- [1- {2- [2-acetylamino-3- (hydroxyphenyl) propionylamino] -3- (4-fluorophenyl) propionyl} -4- (1-methylcarbamoyl -2-naphthalen-2-ylethyl) -piperazin-2-yl] ethyl ester
[652] 2- [2- (tert-butyldimethylsilanyloxy) ethyl] -4- (1-methylcarbamoyl-2-naphthalen-2-ylethyl) -piperazine-1-carboxylic acid tert-butyl ester ( 59) Preparation: di- tert -butyl dicarbonate (26.2 g, 120 mmol) dissolved in dichloromethane (150 mL) at 0 ° C. 2- {3- [2- ( tert -butyldimethylsilanyloxy) Ethyl] -2-oxo-piperazin-1-yl} -N -methyl-3-naphthalen-2-yl-propionamide, 58 , (45.5 g, 100 mol) and triethylamine (32 mL, 230 mmol) Was added to a stirred solution. The resulting solution was allowed to warm to rt for 4 h and stirred. This solution was then diluted with dichloromethane (100 mL) and washed twice with 1 N HCl and twice with aqueous NaHCO ₃ solution. The organic layer was then dried over Na ₂ SO ₄ , filtered and concentrated in vacuo to afford the desired product, which was pure enough to be used without purification.
[653] Preparation of 2- (2-hydroxyethyl) -4- (1-methylcarbamoyl-2-naphthalen-2-ylethyl) piperazine-1-carboxylic acid tert-butyl ester (60): 2- [ 2- ( tert -butyldimethylsilanyloxy) ethyl] -4- (1-methylcarbamoyl-2-naphthalen-2-ylethyl) -piperazine-1-carboxylic acid tert -butyl ester, 59 , ( 15.9 g, 23.5 mmol) and a solution of 1 M tetrabutylammonium fluoride (40 mL) were stirred for 24 hours. The reaction solution was filtered through a pad of silica gel, the filtrate was concentrated in vacuo and the resulting crude product was purified on silica gel (EtOAc / hexane 1: 2, 1: 1, then 5% methanol in EtOAc). The product was obtained.
[654] Preparation of 2- (2-acetoxyethyl) -4- (1-methylcarbamoyl-2-naphthalen-2-ylethyl) -piperazine-1-carboxylic acid tert -butyl ester (61): dichloromethane 2- (2-hydroxyethyl) -4- (1-methylcarbamoyl-2-naphthalen-2-ylethyl) piperazin-1-carboxylic acid tert -butyl ester in (50 mL), 60 , ( 4.4 g, 10 mmol), acetic anhydride (13 mL), pyridine (1 mL) and N, N -dimethylaminopyridine (0.25 g) were stirred for 1.5 h. This solution was then extracted with water and 1M HCl. The organic phase was dried, concentrated in vacuo and the resulting crude product was purified on silica gel (EtOAc / hexane 1: 3 then 1: 1) to afford the desired product.
[655] Acetic acid 2- [4- (1-methylcarbamoyl-2-naphthalen-2-ylethyl-piperazin-2-yl] ethyl ester (62): 2- (2-acetoxyethyl) -4- (1 -Methylcarbamoyl-2-naphthalen-2-ylethyl) -piperazine1-carboxylic acid tert -butyl ester, 61 , (4.8 g, 10 mmol), trifluoroacetic acid (5 mL), and dichloromethane (50 mL) was stirred at rt for 2 h and then concentrated in vacuo The crude product was dissolved in dichloromethane, the organic layer was washed with saturated sodium bicarbonate, dried and concentrated in vacuo to afford the desired product.
[656] Acetic acid-2- [1- (2-N-Boc-amino-3- (4-fluorophenyl) propionyl) -4- (1-methylcarbamoyl-2-naphthalen-2-ylethyl) piperazine Preparation of 2-yl] -ethyl ester (63): Acetic acid 2- [4- (1-methylcarbamoyl-2-naphthalen-2-ylethyl-piperazin-2-yl] in DMF (150 mL) A solution of ethyl ester, 62 , (38.3 g, 100 mmol), hydroxybenzotriazole (16.2 g, 120 mmol) and N-methylmorpholine (132 mL, 120 mmol) was cooled to 0 ° C. and 1- ( 3-dimethylaminopropyl) -3-ethylcarbodiimide (24.9 g, 130 mmol) was added slowly The resulting mixture was stirred for 2 h at 0 ° C., then allowed to warm to rt for another 2 h and stirred The reaction solution was diluted with water and the resulting solid collected by filtration, redissolved in EtOAc, extracted with water, dried and concentrated in vacuo to afford a residue, which was purified on silica gel.
[657] Acetic acid 2- {1- [2-amino-3- (4-fluorophenyl) propionyl] -4- (1-methylcarbamoyl-2-naphthalen-2-ylethyl) piperazin-2-yl} Preparation of ethyl ester (64): (6.3 g, 10 mmol), trifluoroacetic acid (5 mL), and dichloromethane (50 mL) were stirred at rt for 2 h and then concentrated in vacuo. The crude product was dissolved in dichloromethane and the organic layer was washed with saturated sodium bicarbonate and concentrated in vacuo to afford the desired product.
[658] Acetic acid 2- [1- {2- [2-acetylamino-3- (hydroxyphenyl) propionylamino] -3- (4-fluorophenyl) propionyl} -4- (1-methylcarbamoyl- Preparation of 2-naphthalen-2-ylethyl) -piperazin-2-yl] ethyl ester (65): acetic acid 2- {1- [2-amino-3- (4-fluorophenyl) in DMF (150 mL) ) Propionyl] -4- (1-methylcarbamoyl-2-naphthalen-2-ylethyl) piperazin-2-yl] -ethyl ester, 64 , (54.9 g, 100 mmol), hydroxybenzotriazole (16.2 g, 120 mmol), and a solution of N-methylmorpholine (132 mL, 120 mmol) were cooled to 0 ° C. and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide (24.9 g, 130 mmol) was added slowly. The resulting mixture was stirred at 0 ° C. for 2 hours, allowed to warm for an additional 2 hours and stirred. The reaction solution was diluted with water and the resulting solid collected by filtration, redissolved in EtOAc, extracted with water, dried and concentrated in vacuo to afford a residue, which was purified on silica gel.
[659] Other repetitions of this category and repetitions of aspects of the invention pertain to Y units in which R ¹⁵ contains -NH ₂ or -OH, encompassing receptor ligands having the formula:
[660] .
[661] In the formula, R, R ² , R ³ , and R ⁹ are defined in Table X below.
[662]
[663]
[664]
[665] The following is an overview of the synthetic route to prepare analogs 537-596, but other embodiments of 3-ketopiperazine scaffolds, such as 3-hydroxypropyl analogs and the like, can be prepared by modifying this general method. .
[666]
[667] Reagents and conditions: (a) NaOCH ₃ / CH ₃ 0H
[668] Example 10
[669] 2- [4- [2- [2-acetylamino-3- (4-hydroxyphenyl) propionylamino] -3- (4-fluorophenyl) propionyl] -3- (2-hydroxyethyl) Preparation of piperazin-1-yl] -N -methyl-3-naphthalen-2-yl-propionamide (66): acetic acid 2- [1- {2- [2-acetylamino-3 in methanol (50 mL) -(Hydroxyphenyl) -propionylamino] -3- (4-fluorophenyl) propionyl} -4- (1-methylcarbamoyl-2-naphthalen-2-ylethyl) -piperazine-2- To a solution of il] ethyl ester, 65 , (7.5 g, 10 mmol) was added freshly prepared NaOCH ₃ (0.55 g, 10.1 mmol) and the solution was stirred overnight. The solution was dried in vacuo, the resulting residue was partitioned between dichloromethane and water, and the organic layer was dried and concentrated in vacuo to afford the desired product.
[670] Another category of receptor ligand analogs according to the present invention relates to 2,5-substituted 3-ketopiperazines which contain a conformationally restricted ring having the formula:
[671] .
[672] In the formula, the carbon atom indicated by the asterisk may have any atomic arrangement. Table X relates to non-limiting examples of one aspect of analogs of this category, which analogs have the formula:
[673]
[674] In the formula, R, R ² , and R ⁹ are defined in Table XI.
[675]
[676]
[677]
[678] The following is an overview of the synthetic route to prepare analogs 597-656, but other embodiments of the 3-ketopiperazine scaffold can be prepared by modifying this general method.
[679]
[680] Reagents and conditions: (a) 0, N-dimethylhydroxylamine, HOBt, EDCI, N -methylmorpholine, DMF, 0 ° C.
[681]
[682] Reagents and Conditions: (b) LAH, THF, -60 ° C.
[683]
[684] Reagents and Conditions: (c) NaBH (OAC) ₃ , DMF, 0 ° C. to room temperature.
[685]
[686] Reagents and conditions: (d) ClCH ₂ COCl, Et ₃ N, CH ₂ Cl ₂ . 0 ° C. to room temperature.
[687]
[688] Reagents and conditions: (e) N- Boc-amino acids, EDCI, HOBt, DMF.
[689]
[690] Reagents and Conditions: (f) TFA / CH ₂ Cl ₂ , room temperature.
[691]
[692] Reagents and Conditions: (g) EDCI, HOBt, DMF.
[693]
[694] Reagents and conditions: (h) Pd-black, cyclohexene, EtOH / AcOH, reflux.
[695] Preparation of 2,5-substituted 3-ketopiperazine Intermediates
[696] The following is a method for preparing a 2,5-substituted 3-ketopiperazine scaffold intermediate having the formula:
[697] .
[698] In the examples below, R ⁹ is 2-naphthyl and R ¹⁵ is 1-benzyl-1 H -imidazol-4-yl.
[699] 3- (1-benzyl-1 H -Imidazol-4-ylmethyl) -6-naphthalen-2-ylmethylpiperazin-2-one (70)
[700] Preparation of [1- (methoxymethylcarbamoyl) -2-naphthalen-2-ylethyl] carbamic acid tert-butyl ester (67): 2- N- Boc-amino-3-naphthalene in DMF (15 mL) 2-yl propionic acid (2.0 g, 6.3 mmol), 0, N-dimethoxy-hydroxylamine hydrochloride (0.61 g, 6.6 mmol), hydroxybenzotriazole (1.2 g, 9.4 mmol), and N -methyl Morpholine (2 mL, 18.9 mmol) was cooled to 0 ° C. and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide (1.8 g, 9.4 mmol) was added slowly. The resulting mixture was stirred for 2 h at 0 ° C., then allowed to warm to rt for 18 h and stirred. The reaction solution was diluted with water and the resulting solid collected by filtration, redissolved in EtOAc, extracted with water, dried and concentrated in vacuo to give an oily residue which was purified on silica gel to give 2.0 g (88%). White solid).
[701] Preparation of (1-formyl-2-naphthalen-2-ylethyl) carbamic acid tert-butyl ester (68): [1- (methoxymethylcarbamoyl) -2-naphthalene-2 in THF (40 mL) To a solution of -ylethyl ] carbamic acid tert -butyl ester, 67 , (5.0 g, 13.4 mmol) was added LAH (16.7 mL of a 1M solution in THF) at -30 ° C to -25 ° C for about 10 minutes. The reaction was cooled to -55 ° C and stirring continued for 3 hours. After cooling to -60 ° C, the reaction was quenched by addition of citric acid (1: 1 weight ratio) in methanol. The temperature was maintained at about -45 ° C during quenching. The mixture was then allowed to warm to rt, partitioned between EtOAc and water, and the aqueous phase was extracted again with EtOAc. The organic phases were combined, washed with saturated NaCl, dried and concentrated in vacuo to give the crude aldehyde as a white solid, which was used without further purification.
[702] Preparation of 3- (1-benzyl-1 H -imidazol-4-yl) -2- (2- N- Boc-amino-3-naphthalen- 2- ylpropylamino-propionic acid methyl ester (69): crude Aldehyde 1-formyl-2-naphthalen-2-ylethyl) carbamic acid tert -butyl ester, 68 , was dissolved in THF (40 mL) and 2-amino-3- (1-benzyl in DMF (40 mL) -1 H -imidazol-4-yl) propionic acid methyl ester hydrochloride (4.6 g, 13.9 mmol) was added. This solution was cooled to 0 ° C. and sodium triacetoxyborohydride (5.9 g, 27.8 mmol) was added. This suspension was stirred at 0 ° C., allowed to warm to room temperature for 2 hours and then stirred for 18 hours. A saturated aqueous solution of sodium bicarbonate was added until gas evolution ceased. The solution was extracted with diethyl ether, dried and concentrated to give crude product, which was purified on silica gel to give 4.6 g of yellow oil.
[703]
[704] Preparation of 3- (1-benzyl-1 H -imidazol-4-ylmethyl) -6-naphthalen-2-ylmethylpiperazin-2-one (70): 3- (1-benzyl-1 H -imi Dazol-4-yl) -2- (2- N- Boc-amino-3-naphthalen-2-ylpropylamino-propionic acid methyl ester, 69 , (4.6 g, 8.5 mmol) was converted to trifluoroacetic acid / dichloromethane ( 1: 1) (20 mL) and allowed to stir for 1 hour at room temperature The solution was concentrated in vacuo to give an oil which was taken several times with diethyl ether and concentrated in vacuo to give a trace of trifluoroacetic acid. The resulting oil was dissolved in ethanol (35 mL) and refluxed for 3 h The solvent was removed in vacuo to afford the desired product.
[705] Example 11
[706] 2-acetylamino-N- {1- (4-fluorobenzyl) -2- [2- (1H-imidazol-4-ylmethyl) -5-naphthalen-2-ylmethyl-3-oxo-piperazine -1-yl] -2-oxo-ethyl} -3- (4-hydroxyphenyl) propionamide (74)
[707] [2- [2- (1-benzyl-1 H -imidazol-4-ylmethyl) -5-naphthalen-2-ylmethyl-3-oxo-piperazin-1-yl] -1- (4-fluoro Robbenzyl) -2-oxo-ethyl] carbamic acid tert-butyl ester (71) Preparation: 3- (1-benzyl-1 H -imidazol-4-ylmethyl) -6-naphthalene in DMF (15 mL) -2-ylmethyl-piperazin-2-one, 70 , (1.63 g, 4 mmol), (R) -2- N- ( tert -butoxycarbonyl) amino-3- (4-fluorophenyl) A solution of propanoic acid (1.4 g, 4.8 mmol), 1-hydroxybenzotriazole (0.6 g, 4.4 mmol), and N -methylmorpholine (1.3 mL, 12.0 mmol) was cooled to 0 ° C. and 1- ( 3-dimethylaminopropyl) -3-ethylcarbodiimide (1.2 g, 6 mmol) was added slowly. The resulting mixture was stirred for 2 h at 0 ° C., then allowed to warm to rt for another 18 h and stirred. The reaction solution was diluted with water and this solution was extracted with EtOAc. The organic layers were combined, dried and concentrated in vacuo to give a sticky orange solid, which was purified on silica gel to give 1.2 g of a white solid (EtOAc / MeOH 9: 1).
[708] 4- [2-amino-3- (4-fluorophenyl) propionyl] -3- (1-benzyl-1 H -imidazol-4-ylmethyl) -6-naphthalen-2-ylmethylpiperazin- Preparation of 2-one (72): [2- [2- (1-benzyl-1 H -imidazol-4-ylmethyl) -5-naphthalen-2-ylmethyl-3-oxo-piperazin-1- Il] -1- (4-fluorobenzyl) -2-oxo-ethyl] carbamic acid tert -butyl ester, 71 , (30 mg, 0.044 mmol) was dissolved in trifluoroacetic acid / dichloromethane (0.5 mL). . After 1 h the solution was concentrated in vacuo and the residue was purified by reverse phase C ₁₈ preparative HPLC to give 25 mg of white solid.
[709] 2-acetylamino- N- [2- [2- (1-benzyl-1 H -imidazol-4-ylmethyl) -5-naphthalen-2-ylmethyl-3-oxo-piperazin-1-yl] Preparation of -1- (4-fluorobenzyl) -2-oxo-ethyl] -3- (4-hydroxyphenyl) propionamide (73): 4- [2-amino-3- in DMF (4 mL) (4-fluorophenyl) propionyl] -3- (1-benzyl-1 H -imidazol-4-ylmethyl) -6-naphthalen-2-ylmethylpiperazin-2-one, 72 , (0.415 g , 0.615 mmol), N -acetyl-L-tyrosine (0.140 g, 0.615 mmol), 1-hydroxybenzotriazole (0.125 g, 0.922 mmol), and N -methylmorpholine (0.2 mL, 12.0 mmol) Was cooled to 0 ° C. and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide (0.235 g, 1.23 mmol) was added slowly. The resulting mixture was stirred at 0 ° C. for 2 hours, allowed to warm at room temperature for an additional 18 hours, and stirred. The reaction solution was diluted with water and this solution was extracted with EtOAc. The organic layers were combined, dried, concentrated in vacuo and purified by reverse phase C ₁₈ preparative HPLC to yield 0.22 g of a brown-white solid.
[710] 2-acetylamino- N- {1- (4-fluorobenzyl) -2- [2- (1H-imidazol-4-ylmethyl) -5-naphthalen-2-ylmethyl-3-oxo-piperazine Preparation of -1-yl] -2-oxo-ethyl} -3- (4-hydroxyphenyl) propionamide (74): 2-acetylamino- N- [2- [2- (1-benzyl-1 H) -Imidazol-4-ylmethyl) -5-naphthalen-2-ylmethyl-3-oxo-piperazin-1-yl] -1- (4-fluorobenzyl) -2-oxo-ethyl] -3- (4-hydroxyphenyl) propionamide, 73 , (0.22 g, 0.28 mmol) was dissolved in ethanol / acetic acid (4: 1) (3 mL). Cyclohexene (3 mL) and Pd-black were added and the solution was refluxed with periodic supplementation of cyclohexene. The reaction was monitored by TLC, cooled after 2 days and filtered through celite to remove the catalyst. The filtrate was concentrated in vacuo to afford an oil which was purified by reverse phase C ₁₈ preparative HPLC to afford the desired product.
[711] Another aspect of the invention relates to analogs in which two or more of R ² , R ³ and R ⁴ together form a ring, for example a receptor ligand having the formula:
[712] .
[713] In the formula, R, R ⁹ and R ¹⁰ are defined in Table XII.
[714]
[715]
[716]
[717] The following is an overview of the synthetic routes for the preparation of analogs 657-663 and 685-691, but other embodiments and repeats of the 3-ketopiperazine scaffold may be made by modifying this general method.
[718]
[719] Reagents and conditions: (a) HOBt, EDCI, N-methylmorpholine, DMF, O ° C.
[720]
[721] Reagents and Conditions: (b) TFA / CH ₂ Cl ₂ , room temperature.
[722]
[723] Reagents and conditions: (c) HOBt, EDCI, N-methylmorpholine, DMF, O ° C.
[724]
[725] Reagents and Conditions: (b) TFA / CH ₂ Cl ₂ , room temperature.
[726]
[727] Reagents and Conditions: (e) H ₂ , 10% Pd / C; MeOH.
[728] Preparation of 3-ketopiperazine Intermediates
[729] The following is a process for preparing 3-ketopiperazine intermediates having the formula:
[730] .
[731] In this example, R ⁹ is benzyl.
[732] [3- (3-oxo-4-phenethylpiperazin-2-yl) propyl] -carbamic acid benzyl ester (77)
[733] Preparation of (4- N- Cbz-amino-1-phenethylcarbamoylbutyl) carbamic acid tert- butyl ester (75): phenethylamine (12.1 g, 100 mmol), 5-benzyl in DMF (150 mL) Of oxycarbonylamino-2- tert -butoxycarbonylaminopentanoic acid (33.6 g, 100 mmol), hydroxybenzotriazole (16.2 g, 120 mmol), and N -methylmorpholine (132 mL, 120 mmol) The solution was cooled to 0 ° C. and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide (24.9 g, 130 mmol) was added slowly. The resulting mixture was stirred for 2 h at 0 ° C., then allowed to warm to rt for 2 h and stirred. The reaction solution was diluted with water and the resulting solid collected by filtration, redissolved in EtOAc, extracted with water, dried and concentrated in vacuo to afford a residue, which was purified on silica gel.
[734] Preparation of (4-amino-4-phenethylcarbamoylbutyl) carbamic acid benzyl ester (76): (4- N- Cbz-amino-1-phenethylcarbamoylbutyl) carbamic acid tert -butyl ester, 75 , (47.0 g, 100 mmol) was dissolved in 300 ml of a solution prepared from 2: 1: 0.1 parts of dichloromethane, TFA and water. The reaction mixture was stirred for 3 hours. This solvent was removed in vacuo and the residue was treated with 1,2-dichloromethane, which was also removed in vacuo. This was repeated several times to give a crude residue which was used for the next step without further purification.
[735] Preparation of [3- (3-oxo-phenethylpiperazin-2-yl) propyl] -carbamic acid benzyl ester (77): (4-amino-4-phenethylcarbamoylbutyl) in DMF (500 ml) A mixture of carbamic acid benzyl ester, 76 , (36.9 g, 100 mmol), dibromoethane (12.9 mL, 4.36 mmol) and potassium carbonate (69 g, 500 mmol) was stirred at 55 ° C for 18 h. The reaction mixture was cooled with silver, treated with 1M KHS0 ₄ and the resulting solution was extracted with ethyl acetate. The crude product was purified on silica (sequential elution of EtOAc with EtOAc / hexane mixtures 1: 2, 1: 1, 100% EtOAc, then 5% MeOH) to afford the desired product.
[736] Example 12
[737] 2- (3- (3-aminopropyl) -4- {3- (4-fluorophenyl) -2-[(1,2,3,4-tetrahydroquinoline-3-carbonyl) amino] propionyl } -2-oxo-piperazin-1-yl) -3-naphthalen-2-yl propionic acid methyl ester (82)
[738] (3- {1- [2- N- Boc-amino-3- (4-fluorophenyl) propionyl] -3-oxo-4-phenethylpiperidin-2-yl} propyl) -carbamic acid benzyl ester Preparation of (78): [3- (3-oxo-4-phenethyl-piperazin-2-yl) propyl] -carbamic acid benzyl ester in DMF (15 mL), 77 , (3.95 g, 10 mmol), ( R) -2- N- ( tert -butoxycarbonyl) amino-3- (4-fluorophenyl) propionic acid (3.40 g, 12 mmol), 1-hydroxybenzotriazole (1.62 g, 12 mmol), And a solution of N -methylmorpholine (13 mL, 12 mmol) was cooled to 0 ° C. and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide (2.49 g, 13 mmol) was added slowly. The resulting mixture was stirred at 0 ° C. for 2 h, then allowed to warm to rt for 2 h and stirred. The reaction solution was diluted with water and the resulting solution was extracted with EtOAc, dried and concentrated in vacuo to afford the desired product.
[739] Of (3- {1- [2-amino-3- (4-fluorophenyl) propionyl] -3-oxo-4-phenethylpiperazin-2-yl} propyl) -carbamic acid benzyl ester (79) Preparation: (3- {1- [2- N- Boc-amino-3- (4-fluorophenyl) propionyl] -3-oxo-phenethylpiperidin-2-yl} propyl) -carbamic acid benzyl ester , 78 , (6.6 g, 10 mmol), a solution of trifluoroacetic acid (5 mL), and dichloromethane (50 mL) was stirred at room temperature for 2 hours and then concentrated in vacuo. The crude product was dissolved in dichloromethane and the organic layer was washed with saturated sodium bicarbonate, dried and concentrated in vacuo to afford the desired product.
[740] 3- [2- [2- (3- N- Cbz-aminopropyl) -3-oxo-phenethylpiperazin-1-yl] -1- (4-fluorobenzyl) -2-oxo-ethylcarba Moyl] -3,4-dihydro-1 H -isoquinoline-2-carboxylic acid tert- butyl ester (80): (3- {1- [2-amino-3- in DMF (50 mL) (4-fluorophenyl) propionyl] -3-oxo-4-phenethylpiperazin-2-yl} propyl) -carbamic acid benzyl ester, 79 , (5.6 g, 10 mmol), N- Boc-1, 2,3,4-tetrahydroisoquinoline-3-carboxylic acid (3.8 g, 10 mmole), hydroxybenzotriazole (1.62 g, 12 mmol), and N -methylmorpholine (13 mL, 12 mmol) The solution of was cooled to 0 ° C. and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide (2.49 g, 13 mmol) was added slowly. The resulting mixture was stirred at 0 ° C. for 2 hours, allowed to warm at room temperature for a further 2 hours, and stirred. The reaction solution was diluted with water and the resulting solution was extracted with EtOAc, dried and concentrated in vacuo to afford the crude product, which was purified on silica gel.
[741] [3- (1- {3- (4-fluorophenyl) -2-[(1,2,3,4-tetrahydroisoquinoline-3-carbonyl) amino] propionyl} -3-oxo-4 Preparation of -phenethylpiperazin-2 -yl) propyl] carbamic acid benzyl ester (81): 3- [2- [2- (3- N- Cbz-aminopropyl) -3-oxo-4-phenethyl pipe Razin-1-yl] -1- (4-fluorobenzyl) -2-oxo-ethylcarbamoyl] -3,4-dihydro-1 H -isoquinoline carboxylic acid tert -butyl ester, 80 , ( 8.2 g, 10 mmol), trifluoroacetic acid (5 mL), and a solution of dichloromethane (50 mL) were stirred at room temperature for 2 hours and then concentrated in vacuo. The crude product was dissolved in dichloromethane and the organic layer was washed with saturated sodium bicarbonate, dried and concentrated in vacuo to afford the desired product.
[742] 2- (3- (3-aminopropyl) -4- {3- (4-fluorophenyl) -2-[(1,2,3,4-tetrahydroisoquinoline-3-carbonyl) amino] propy Preparation of Oyl} -2-oxo-piperazin-1-yl) -3-naphthalen-2-yl propionic acid methyl ester (82): [3- (1- {3- (4-fluorophenyl) -2- [(1,2,3,4-tetrahydroisoquinoline-3-carbonyl) amino] propionyl} -3-oxo-4-phenethylpiperazin-2-yl) propyl] carbamic acid benzyl ester, 81 , (7.2 g, 10 mmol) was suspended in methanol (100 ml) and hydrogenated in the presence of 10% Pd / C for 24 hours at 40 psi. The solution was filtered to remove the catalyst and the crude product was purified by preparative HPLC using a linear gradient of acetonitrile in water with 0.1% TFA to afford the desired product.
[743] The invention also relates to a method of treating one or more disease states. One aspect of the present invention is directed to an animal subject in need of treatment, insulin resistance, glucose tolerance, type 2 diabetes mellitus, coronary artery disease, elevated blood pressure, hypertension, dyslipidaemia, cancer (eg, endometrium, cervix). , Ovary, breast, prostate, gallbladder, colon), menstrual disorders, hirsutism, infertility, gallbladder disease, limited lung disease, sleep apnea, gout, osteoarthritis, and thromboembolic disease The method comprises administering to the subject a compound as described above.
[744] Another aspect of the invention provides a subject in need of treatment for a weight disorder, CNS depression, behavioral disorders, memory-related disorders, cardiovascular function, inflammation, sepsis, infection shock, heart shock, blood volume reduction shock, sexual dysfunction, erection A method of treating one or more disorders selected from the group consisting of dysfunction, muscle atrophy, nerve growth and recovery related diseases, and intrauterine fetal growth, the method comprising administering to the subject a compound as described above do.
[745] Certain embodiments of the invention relate to a method of controlling weight disorders selected from the group consisting of obesity, anorexia and cachexia.
[746] Melanocortin Functional Activity and Selectivity
[747] Functional activity can be assessed using a variety of methods known in the art. Examples of such methods are the measurement of a second messenger response, specifically cAMP, which causes a color reaction upon accumulation of a second messenger component, such as cAMP. Modified cell systems are used, such as those described in Chen et al ., 1995 ( Anal Biochem . 1995, 226, 349-54), Cytosensor Microphysiometer techniques (see Boyfield et al., 1996), or are generated by compounds of the present invention. The study of the physiological effects of the invention can be applied by using the compounds of the present invention alone or in combination with natural or synthetic MSH-peptides.
[748] Compounds of the present invention will preferentially interact (ie, selectively) interact with MC-4 and / or MC-3 over other melanocortin receptors. When the compounds are administered to humans or other animals, selectivity is particularly important in order to minimize the number of side effects associated with their administration. MC-3 / MC-4 selectivity of a compound is herein referred to as MC- relative to EC ₅₀ of the compound for the MC-3 (EC ₅₀ -MC-3) / MC-4 (EC ₅₀ -MC-4) receptor. Defined as the ratio of EC ₅₀ to 1 receptor (“EC ₅₀ -MC-1”), EC ₅₀ values are measured as described above. The formula is:
[749] MC-3 selectivity = [EC ₅₀ -MC-1] / [EC ₅₀ -MC-3]
[750] MC-4 selectivity = [EC ₅₀ -MC-1] / [EC ₅₀ -MC-4]
[751] When the aforementioned "MC-3 selectivity" ratio is at least about 10, preferably at least about 100, and more preferably at least about 500, the compound is defined herein as being "selective to the MC-3 receptor". .
[752] When the aforementioned "MC-4 selectivity" ratio is at least about 10, preferably at least about 100, more preferably at least about 500, the compound is defined herein as "selective to the MC-4 receptor".
[753] Method of use and composition:
[754] The invention also relates to a composition containing the receptor ligand described above. By way of example, the present invention relates to a pharmaceutical composition comprising:
[755] a) an effective amount of a compound, or one or more pharmaceutically acceptable salts thereof, and
[756] b) remaining amount of pharmaceutically acceptable carrier, excipient, and auxiliary ingredients.
[757] A "safely effective amount" of a compound according to the invention, in animals, preferably mammals, and more preferably in human subjects, is characterized by MC-4 and / or MC-3 without severe side effects (toxic, hypersensitivity, or allergic reactions). A balanced amount is an effective benefit / risk ratio that is effective for interacting with the receptor and used in the manner of the present invention. A particular "safe effective amount" refers to the specific condition to be treated, the patient's state of health, the duration of treatment, the nature of the combination therapy (if any), the particular dosage form employed, the excipient used, the solubility of the compound of formula (I) therein, And factors such as the dosage regimen required for the composition.
[758] In addition to the present compounds, the compositions of the present invention contain one or more pharmaceutically acceptable excipients. As used herein, the expression "pharmaceutically acceptable excipient" means one or more compatible solid or liquid components suitable for administration to an animal, preferably a mammal, more preferably a human. As used herein, the term "miscible" means that the components of the composition may be mixed with the present compound and with each other in such a way that no interaction occurs that would substantially reduce the pharmaceutical efficacy of the composition under normal use conditions. Means that. Pharmaceutically acceptable excipients, of course, must be sufficiently high purity and sufficiently low toxicity to be suitable for application to the animal to be treated, preferably a mammal, more preferably a human.
[759] Examples of materials that can be provided as pharmaceutically acceptable excipients or components thereof include sugars such as lactose, glucose and sucrose; Starch such as corn starch and potato starch; Cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, and methyl cellulose; Powdered tragacanth; malt; gelatin; Talc; Solid lubricants such as stearic acid and magnesium stearate; Vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and cacao oil; Polyols such as propylene glycol, glycerin, sorbitol, mannitol, and polyethylene glycol; Agar; Alginic acid; Wetting agents and lubricants such as sodium lauryl sulfate; coloring agent; Flavoring agents; Tableting agents; Stabilizer; Antioxidants; Preservatives; Pyrogen-free water; Isotonic saline; And buffers such as phosphate, citrate and acetate.
[760] The choice of pharmaceutically acceptable excipients for use with the present compounds is basically determined by the manner in which the compounds are administered. When the main compound is injected, the preferred pharmaceutically acceptable excipient is sterile water, saline, or mixtures thereof, the pH of which is preferably adjusted to about 4-10 with pharmaceutical buffer; Miscible suspending agents may also be preferred.
[761] Specifically, pharmaceutically acceptable excipients for systemic administration include sugars, starches, celluloses and derivatives thereof, malt, gelatin, talc, calcium sulfate, lactose, vegetable oils, synthetic oils, polyols, alginic acid, phosphates, acetates and sheets Rate buffers, emulsifiers, isotonic saline, and water free of pyrogenic substances. Preferred excipients for parenteral administration include propylene glycol, ethyl oleate, pyrrolidone, ethanol, and sesame oil. Preferably, the pharmaceutically acceptable excipient in the composition for parenteral administration contains about 90% by weight of the total composition.
[762] The composition of the present invention is preferably provided in unit dosage form. A "unit dosage form" as used herein, according to good medical practice, is a quantity of Formula I suitable for administration to an animal, preferably a mammal, more preferably a human, in a single dose. The composition of this invention containing the compound of. These compositions preferably contain about 1 mg to about 750 mg, more preferably about 3 mg to about 500 mg, more preferably about 5 mg to about 300 mg of the compound of formula (I).
[763] Based on their ability to act or antagonize MC-4 and / or MC-3 receptors, the invention also provides ligands described herein in the treatment of obesity and other body weight disorders, including, for example, anorexia and cachexia. It is about the use of. These compounds include, but are not limited to, insulin resistance, glucose tolerance, type 2 diabetes mellitus, coronary artery disease, elevated blood pressure, hypertension, dyslipidemia, cancer (eg, endometrium, cervix, ovary, breast, prostate, gallbladder) , Colon), menstrual irregularities, hirsutism, infertility, gallbladder disease, limited lung disease, sleep apnea, gout, osteoarthritis, and thromboembolic disorders, and methods of treating disorders due to weight disorders. The invention also provides for the treatment of disorders related to behavior, memory (including learning), cardiovascular function, inflammation, sepsis, cardiac and blood volume shock, sexual dysfunction, male erection, muscle atrophy, nerve growth and recovery, intrauterine fetal growth, and the like. It is about.
[764] As used herein, the terms treatment and treatment mean, at least, that the administration of a compound of the invention alleviates a disorder that acts through the MC-3 or MC-4 receptor. Thus, the term means that a mammal, especially the mammal, has not yet been diagnosed as having a disease but prevents the disease state from occurring when it is easy to acquire the disease; Inhibit the development of the disease state; And / or alleviating or reversing a disease state.
[765] The compounds of the present invention may thus be formulated into pharmaceutical compositions for use in the treatment or prevention of such conditions. Standard pharmaceutical formulation techniques are used, such as those disclosed in Remington's Pharmaceutical Sciences , Mack Publishing Company, Easton, Pa., Latest edition and Peptide and Protein Drug Delivery , Marcel Dekker, NY, 1991.
[766] The compositions of the present invention can be in any of a variety of forms suitable for (as examples) oral, rectal, topical, nasal, eye, transdermal, pulmonary or parenteral administration. Depending on the particular route of administration desired, various pharmaceutically acceptable excipients well known in the art may be used. These include solid or liquid fillers, diluents, hydrophilic agents, surfactants, and encapsulating materials. Any pharmaceutically active substance may be included that does not substantially interfere with the inhibitory action of the compound of formula (I). The amount of excipient used with the compound of formula I is sufficient to provide a substantial amount of the substance for administration per unit dose of the compound. Techniques and compositions for preparing dosage forms useful in the methods of the invention are described in the following references, all of which are incorporated herein by reference: Modern Pharmaceutics , chapters 9 and 10 (Banker & Rhodes, Editors, 1979); Lieberman et al., Pharmaceutical Dosage Forms : Tablets (1981); And Ansel, Introduction to Pharmaceutical Dosage Forms 2d Edition (1976).
[767] Various oral dosage forms are available and include solid forms such as tablets, capsules, granules and bulk powders. These oral forms contain a safe effective amount, generally at least about 5%, and preferably at least about 25% to about 50% of the compound of formula (I). Tablets contain suitable binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, flow inducing agents, and melting agents, and may be compressed, tablet milled, interior coating, sugar coating, film coating, or multiple compression. Liquid oral dosage forms contain suitable solvents, preservatives, emulsifiers, suspending agents, diluents, sweeteners, melting agents, colorants and flavoring agents, and suspensions reconstituted from aqueous solutions, emulsions, suspensions, solutions and / or non-foamable granules, and Foamable formulations reconstituted from foamable granules.
[768] Pharmaceutically acceptable excipients suitable for the preparation of unit dosage forms for oral administration are well known in the art. Tablets typically contain conventional pharmaceutically compatible adjuvants and include as inert diluents such as calcium carbonate, sodium carbonate, mannitol, lactose and cellulose; Examples of binders include starch, gelatin, polyvinylpyrrolidone and sucrose; Examples of disintegrants include starch, alginic acid and croscarmellose; Lubricants include magnesium stearate, stearic acid and talc. Lubricants, such as silicon dioxide, can be used to improve the flow characteristics of the powder mixture. Colorants such as FD & C dyes may be added for appearance. Sweeteners and flavoring agents such as aspartame, saccharin, menthol, peppermint, and fruit flavors are useful aids for chewing tablets. Capsules typically contain one or more solid diluents described above. The choice of excipient components depends on secondary considerations, which are not critical to the purpose of the present invention, such as taste, cost and storage stability, and can be readily made by those skilled in the art.
[769] Oral administration compositions also include liquid solutions, emulsions, suspensions, and the like. Pharmaceutically acceptable excipients suitable for the preparation of such compositions are known in the art. Excipient components typical for syrups, elixirs, emulsions and suspensions include ethanol, glycerol, propylene glycol, polyethylene glycol, liquid sucrose, sorbitol and water. For suspensions, typical suspending agents are methyl cellulose, sodium carboxymethyl cellulose, Avicel RC-591, tragacanth and sodium alginate; Typical humectants include lecithin and polysorbate 80; And typical preservatives include methyl paraben, propyl paraben and sodium benzoate. Oral liquid compositions may also contain one or more ingredients such as the sweeteners, flavors, and coloring agents disclosed above.
[770] Such compositions are coated by conventional methods, typically with a pH or time dependent coating, such that the compounds of the present invention are released from the gastrointestinal tract near the desired topical application or at various times when the desired action is extended. Such dosage forms typically include, but are not limited to, one or more cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropyl methyl cellulose phthalate, ethyl cellulose, Eudragit Coatings, waxes, and shellacs.
[771] Since the compounds of the present invention are naturally peptidic, preferred methods of administration are parenteral (more preferably intravenous) or nasal administration in the form of unit dosage forms. Preferred unit dosage forms include suspensions and solutions containing a safe effective amount of the compound of formula (I). When administered parenterally, unit dosage forms will typically contain from about 1 mg to about 3 g, more typically from about 10 mg to about 1 g of a compound of Formula I, although the amount of compound administered is It will depend on its relative affinity for the MC-4 / MC-3 receptor subtype, its selectivity for other receptors including other melanocortin receptors and the like.
[772] The composition of the present invention may optionally comprise other drug actives.
[773] Other compositions used to achieve systemic delivery of the compounds of the present invention include sublingual and buccal dosage forms. Such compositions typically comprise one or more soluble filler materials such as sucrose, sorbitol and mannitol; And binders as examples acacia, microcrystalline cellulose, carboxymethyl cellulose and hydroxypropyl methyl cellulose. Lubricants, lubricants, sweeteners, colorants, antioxidants and flavoring agents disclosed above may also be included.
[774] Dosing method:
[775] As shown, the compositions of the present invention can be administered locally or systemically. Systemic application is any method of introducing a compound of Formula I into body tissue, such as intraarticular, intradural, epidural, intramuscular, transdermal, vein, intraperitoneal, subcutaneous, sublingual, rectal, nasal, lung, and oral Administration. The compounds of formula (I) of the invention are preferably administered systemically, more preferably parenterally and most preferably via intravenous injection.
[776] The particular dosage and duration of treatment of the compound to be administered, and whether the treatment is local or systemic, are interdependent. Dosage and treatment regimen also depend on factors such as the particular compound of formula (I) used, the indications for treatment, the individual characteristics of the subject (eg body weight), compliance with the treatment regimen, and the presence and severity of any side effects of treatment Will be different.
[777] Typically, for adult humans of about 70 kg body weight, from about 1 mg to about 6 g, more typically from about 100 mg to about 3 g, of a compound of formula (I) apply for systemic administration. It is to be understood that these dosage ranges are exemplary only and that the daily dosage may be adjusted differently depending on the factors listed above.
[778] As known and practiced in the art, all parenteral formulations must be sterile. In the case of mammals, especially in humans (assuming a weight of about 70 kg), the individual dosage is preferably from about 0.001 mg to about 100 mg.
[779] Preferred method of systemic administration is intravenous delivery. When using this delivery method, an individual dosage of about 0.01 mg to about 100 mg, preferably about 0.1 mg to about 100 mg is preferred.
[780] In the above, the compounds of the present invention may, of course, be administered alone or as a mixture, and the composition may also further comprise additional drugs or excipients suitable for the condition.
[781] The compounds of the present invention can be delivered to the desired site in the body by using a suitable drug delivery system. Drug delivery systems are well known in the art. By way of example, drug delivery techniques useful for the compounds of the present invention may be transported through biological barriers (see, eg, Zlokovic, BV, Pharmaceutical Research , Vol. 12, pp. 1395-1406 (1995)). Is the inclusion into the active molecule. Particular examples consist of coupling a compound of the present invention to insulin fragments to achieve transport through blood brain obstructions (Fukuta, M., et al . , Pharmaceutical Res. , Vol. 11, pp. 1681-1688 (1994) ). General reviews of techniques for drug delivery suitable for the compounds of the present invention are described in Zlokovic, BV, Pharmaceutical Res ., Vol. 12, pp. 1395-1406 (1995) and Pardridge, WM, Pharmacol. Toxicol. , Vol. 71, pp. 3-10 (1992). See 124.

权利要求:
Claims (25)
[1" claim-type="Currently amended] A compound of the formula: comprising both enantiomeric and diastereomeric forms and pharmaceutically acceptable salts thereof:

[Wherein A is
a) non-aromatic carbocyclic ring;
b) aromatic carbocyclic rings;
c) non-aromatic heterocyclic rings;
d) aromatic heterocyclic rings;
A stereoscopically restricted ring system selected from the group consisting of; The ring contains 5 to 8 atoms;
W is a pendant unit having the formula:

[Wherein R is
a) non-aromatic carbocyclic ring;
b) aromatic carbocyclic rings;
c) non-aromatic heterocyclic rings;
d) aromatic heterocyclic rings;
It is selected from the group consisting of; The ring contains 3 to 12 atoms;
J is selected from the group consisting of:
i) - [C (R - ; and ") _{d] k} wherein each R" is independently hydrogen, C ₁ ~ C ₁₂ straight or branched alkyl, -SUB, two R "units carboxylic together with the oxygen atoms A carbonyl or heterocyclic fused ring, bicyclic, which may form a carbonyl unit, wherein two R "units from any J unit or R" units and R 'units from any T unit together contain 3 to 7 atoms A ring, or a spiroannulated ring, may form an index d having a value of 1 or 2, and an index k having a value of 1 or 2;
ii) ;
iii) -NR'-; R 'is hydrogen, C ₁ -C ₆ linear or branched alkyl or SUB unit;
iv) -O-;
v) -S-;
vi) -P (O)-or -P (O) _2- ;
vii) and mixtures thereof;
L is a linking unit;
B is
a) hydrogen;
b) substituted or unsubstituted aromatic carbocyclic rings;
c) substituted or unsubstituted aromatic heterocyclic ring; And
d) contains units selected from the group consisting of mixtures thereof.] Y is a pendant unit containing one or more heteroatoms;
Z is a pendant unit, which contains an aromatic or non-aromatic ring moiety.
[2" claim-type="Currently amended] The compound or mixture thereof according to claim 1, wherein A is a stereostructically restricted ring system selected from the group consisting of:

[In the formula, the carbon atoms marked with an asterisk may have any stereochemical configuration.].
[3" claim-type="Currently amended] The compound of claim 1 or 2, wherein W has the formula:

[Wherein J is-(CH ₂ )-, -C (O)-and mixtures thereof;
L units are selected from the group consisting of:
i) -C (O) NH-;
ii) -C (O) NHC (O)-;
iii) -NHC (O)-;
iv) -NH-;
v)-(CH ₂ ) _b NH-; Wherein b is 1 to 3; And
vi) -NH (CH ₂ ) _b- ; Wherein b is 1 to 3;
R is substituted or unsubstituted aryl;
B is hydrogen or a unit having the formula:

[Wherein, R ² , R ³ and R ⁴ units are independently selected from the following groups:
a) a ring containing:
a) substituted or unsubstituted aromatic carbocyclic ring;
b) substituted or unsubstituted aromatic heterocyclic ring;
c) and mixtures thereof;
b) hydrogen;
c) a unit selected from the group consisting of -CH ₂ C (O) CH ₃ , -NHC (O) CH ₃ , NHC (O) CH ₂ CH ₃ , and -NHC (O) CH ₂ CH ₂ CH ₃ ;
d) two or more of two or more R ² , R ³ or R ⁴ together may form a ring;
e) mixtures thereof]].
[4" claim-type="Currently amended] The compound of any one of claims 1-3, wherein W has the formula:
,
[Wherein R is selected from the group consisting of phenyl, benzyl, 3-fluorophenyl, 4-fluorophenyl, 3,5-difluorophenyl, 4-chlorophenyl, 4-hydroxyphenyl, and mixtures thereof do].
[5" claim-type="Currently amended] The compound according to any one of claims 1 to 4, wherein W has the formula

Or a compound having the formula:

[Wherein, R ² , R ³ and R ⁴ units are each independently selected from the following groups:
a) a ring containing:
i) a substituted or unsubstituted aromatic carbocyclic ring;
ii) substituted or unsubstituted aromatic heterocyclic ring;
iii) and mixtures thereof;
b) hydrogen;
c) a unit selected from the group consisting of -CH ₂ C (O) CH ₃ , -NHC (O) CH ₃ , -NHC (O) CH ₂ CH ₃ , and -NHC (O) CH ₂ CH ₂ CH ₃ ; And
d) mixtures thereof.
[6" claim-type="Currently amended] A compound according to any one of claims 1 to 5, wherein R ² is -NHC (O) CH ₃ , and R ⁴ is benzyl, 2-imidazolylmethyl, 4-imidazolylmethyl, 4-fluorobenzyl , 4-hydroxybenzyl, and 4-acetoxybenzyl.
[7" claim-type="Currently amended] 7. A compound according to any one of claims 1 to 6, wherein at least two of R ² , R ³ and R ⁴ together form a ring.
[8" claim-type="Currently amended] 8. A compound according to any one of claims 1 to 7, wherein W has the formula:
.
[9" claim-type="Currently amended] The compound of any one of claims 1 to 8, wherein Y has the formula:
-(CH ₂ ) _b -R ¹⁵
[Wherein, R ¹⁵ contains a hetero atom and the index b is 1 to 4].
[10" claim-type="Currently amended] The compound of claim 1, wherein R ¹⁵ is an ester selected from the group consisting of:
; or
A compound that is an amide selected from the group consisting of:
.
[11" claim-type="Currently amended] The compound according to claim 1, wherein R ¹⁵ is a unit selected from the group consisting of:

[Wherein X = 0, = S, NR ¹⁶ , and mixtures thereof, R ¹⁶ is hydrogen, methyl, cyano, hydroxy, nitro, and mixtures thereof; Index z is from 0 to 5;
[12" claim-type="Currently amended] The compound of claim 11, wherein R ¹⁵ has the formula:
.
[13" claim-type="Currently amended] 13. Compounds according to claim 12, wherein Y has the formula:
.
[14" claim-type="Currently amended] The compound of claim 12, wherein R ¹⁵ is selected from the group consisting of:
i) triazoles having the formula:
;
ii) tetrazolyl having the formula:

iii) thiazolyl, 2-methylthiazolyl, 4-methylthiazolyl, 5-methylthiazolyl having the formula:

iv) 1,3,4-thiadiazolyl, 2-methyl-1,3,4-thiadiazolyl having the formula:

v) 1,2,5-thiadiazolyl, 3-methyl-1,2,5-thiadiazolyl having the formula:

vi) oxazolyl, 2-methyloxazolyl, 4-methyloxazolyl, 5-methyloxazolyl having the formula:

vii) imidazolyl, 2-methylimidazolyl, 5-methylimidazolyl having the formula:

viii) 5-methyl-1,2,4-oxadiazolyl, 2-methyl-1,3,4-oxadiazolyl, 5-amino-1,2,4-oxadiazolyl having the formula:

ix) 1,2-dihydro [1,2,4] triazol-3-one-1-yl, 2-methyl-1,2-dihydro [1,2,4] triazole- having the formula 3-on-5-day:

x) oxazolidin-2-one-3-yl having the formula: 4,4-dimethyloxazolidin-2-one-3-yl; Imidazolidin-2-one-1-yl; 1-Methylimidazolidin-2-one-yl:

xi) 2-methyl-1,3,4-oxadiazolyl, 2-amino-1,3,4-oxadiazolyl, 2- (N, N-dimethylamino) -1,3,4 having the formula Oxadiazolyl:

[15" claim-type="Currently amended] The compound of claim 12, wherein R ¹⁵ is selected from the group consisting of:
i) pyridinyl units having the formula:

ii) pyrimidinyl units having the formula:

ii) piperidinyl units having the formula:
.
[16" claim-type="Currently amended] The compound of claim 12, wherein R ¹⁵ is selected from the group consisting of:
Amino, guanidino, guanyl, amidino, pyrrolyl, 2H-pyrrolyl, 3H-pyrrolyl, pyrazolyl, 2H-imidazolyl, 1,2,3-triazole, 1,2,4-tria Sol, isoxazolyl, oxazolyl, 1,2,3-isoxazolyl, 1,2,4-oxadiazolyl, 2H-pyranyl, 4H-pyranyl, 2H-pyran-2-one-yl, pyri Diyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, s-triazinyl, 4H-1,2-oxazinyl, 2H-1,3-oxazinyl, 1,4-oxazinyl, morpholinyl , Azepinyl, oxepinyl, 4H-1,2-diazepinyl, indenyl, 2H-indenyl, benzofuranyl, isobenzofuranyl, indolyl, 3H-indolyl, 1H-indolyl, benz Oxazolyl, 2H-1-benzopyranyl, quinolinyl, isoquinolinyl, quinazolinyl, 2H-1,4-benzoxazinyl, pyrrolidinyl, pyrrolidoneyl, pyrrolinyl, quinoxalinyl , Pyrrolyl, benzimidazolyl, and mixtures thereof.
[17" claim-type="Currently amended] The compound of any of claims 1-16, wherein Z has the formula:

[Wherein R ⁸ is hydrogen; R ⁹ is phenyl, benzyl, 1-naphthyl, 2-naphthyl, 1-naphthylmethyl, 2-naphthylmethyl; R ¹⁰ is hydrogen, -C (X) N (R 16) 2, -N (R 16) 2 -N + (R 16) 3 D -, -C (X) N + (R 16) 3 D -, -NR ¹⁶ C (X) R ¹⁷ and mixtures thereof; R ¹⁶ is hydrogen, C ₁ -C ₁₀ alkyl, or a mixture thereof; R ¹⁷ is C ₁ -C ₁₆ linear or branched, substituted or unsubstituted alkyl, C ₇ -C ₁₆ linear or branched, substituted or unsubstituted alkylenearyl; X is oxygen, sulfur, = NR ¹⁶ , and mixtures thereof; D is a salt forming anion].
[18" claim-type="Currently amended] 18. The compound of any one of claims 1 to 17, wherein R ¹⁰ is -CO ₂ H, -CO ₂ CH ₃ , -CONH ₂ , and -CONHCH ₃ .
[19" claim-type="Currently amended] 19. The compound of any of claims 1-18, wherein R ⁹ is phenyl, benzyl, 2-naphthyl or 2-naphthylmethyl.
[20" claim-type="Currently amended] 20. A compound according to any one of claims 1 to 19 containing a scaffold selected from the group consisting of:




[Wherein R is from the group consisting of phenyl, benzyl, 3-fluorophenyl, 4-fluorophenyl, 3,5-difluorophenyl, 4-fluorophenyl, 4-hydroxyphenyl, and mixtures thereof Selected; R ² is a unit selected from the group consisting of hydrogen, —CH ₂ C (O) CH ₃ , —NHC (O) CH ₃ , —NHC (O) CH ₂ CH 3, and —NHC (O) CH ₂ CH ₂ CH ₃ ego; R ³ is hydrogen; R ⁴ is benzyl, 2-imidazolylmethyl, 4-imidazolylmethyl, 4-fluorobenzyl, 4-hydroxybenzyl, 4-acetoxybenzyl, 2-imidazolylmethyl, 4-imidazolylmethyl , 2-phenylethyl, 1-naphthylmethyl, and 2-naphthylmethyl; R ⁹ is phenyl, benzyl, 1-naphthyl, 2-naphthyl, 1-naphthylmethyl, 2-naphthylmethyl; R ¹⁰ is hydrogen, —CO ₂ CH ₃ , —CO ₂ H; -CONH ₂ ; And -CONHCH ₃ ].
[21" claim-type="Currently amended] The compound of any one of claims 1-20, wherein L is selected from the group consisting of:

[Wherein R ¹¹ is hydrogen, linear or branched C ₁ -C ₁₀ alkyl, hydroxyl, —SUB, or mixtures thereof; R ¹² is C ₁ -C ₁₆ linear or branched, substituted or unsubstituted alkylene, substituted or unsubstituted phenylene, or mixtures thereof; Or R ¹¹ and R ¹² units may form a ring together; X is oxygen, sulfur, = NR ¹¹ , and mixtures thereof; t is 0 or 1].
[22" claim-type="Currently amended] The compound of any one of claims 1-21, wherein the SUB unit is selected from the group consisting of:

[Wherein R ³⁰ is hydrogen, C ₁ -C ₂₀ linear or branched alkyl, C ₆ -C ₂₀ aryl, C ₇ -C ₂₀ alkylenearyl, and mixtures thereof; M is hydrogen or a salt forming cation].
[23" claim-type="Currently amended] A pharmaceutical composition comprising:
A) A compound of the formula: comprising a safe effective amount of both its enantiomeric and diastereomeric forms and pharmaceutically acceptable salts:

[Wherein A is
a) non-aromatic carbocyclic ring;
b) aromatic carbocyclic rings;
c) non-aromatic heterocyclic rings;
d) aromatic heterocyclic rings;
A stereoscopically restricted ring system selected from the group consisting of; The ring contains 5 to 8 atoms;
W is a pendant unit having the formula:

[Wherein R is
a) non-aromatic carbocyclic ring;
b) aromatic carbocyclic rings;
c) non-aromatic heterocyclic rings;
d) aromatic heterocyclic rings;
It is selected from the group consisting of; The ring contains 3 to 12 atoms;
J is selected from the group consisting of:
i) - [C (R - ; and ") _{d] k} wherein each R" is independently hydrogen, C ₁ ~ C ₁₂ straight or branched alkyl, -SUB, two R "units carboxylic together with the oxygen atoms A carbonyl or heterocyclic fused ring, bicyclic, which may form a carbonyl unit, wherein two R "units from any J unit or R" units and R 'units from any T unit together contain 3 to 7 atoms A ring, or a spiroannulated ring, may form an index d having a value of 1 or 2, and an index k having a value of 1 or 2;
ii) ;
iii) -NR'-; R 'is hydrogen, C ₁ -C ₆ linear or branched alkyl or SUB unit;
iv) -O-;
v) -S-;
vi) -P (O)-or -P (O) _2- ;
vii) and mixtures thereof;
L is a linking unit;
B is
a) hydrogen;
b) substituted or unsubstituted aromatic carbocyclic rings;
c) substituted or unsubstituted aromatic heterocyclic ring; And
d) contains units selected from the group consisting of mixtures thereof] Y is a pendant unit containing one or more heteroatoms;
Z is a pendant unit, which contains an aromatic or carbocyclic ring moiety; And
B) remaining amount of carrier, excipient, and auxiliary ingredients.
[24" claim-type="Currently amended] In animal subjects in need of treatment, insulin resistance, glucose tolerance, type 2 diabetes mellitus, coronary artery disease, elevated blood pressure, hypertension, dyslipidemia, cancer (eg, endometrium, cervix, ovary, breast, prostate, gallbladder, and Colon), menstrual irregularity, hirsutism, infertility, gallbladder disease, limited lung disease, sleep apnea, gout, osteoarthritis, and thromboembolic disease, the method of treating a disorder, comprising any one of claims 1 to 22 A method comprising administering a compound according to claim to said subject.
[25" claim-type="Currently amended] In animals in need of treatment, weight disorders, CNS depression, behavioral disorders, memory-related disorders, cardiovascular function, inflammation, sepsis, infection shock, heart shock, blood loss shock, sexual dysfunction, erectile dysfunction, muscle atrophy, nerves A method of treating a disorder selected from the group consisting of growth and recovery related diseases, and intrauterine fetal growth, the method comprising administering a compound according to any one of claims 1 to 22 to said subject.

类似技术:

---

公开号 | 公开日 | 专利标题

---

EP0772590B1|2002-10-09|Thrombin inhibitors

---

RU2012556C1|1994-05-15|Method of synthesis of cycloalkylglutaramide derivatives or theirs pharmaceutically acceptable salts

---

US6596687B1|2003-07-22|Cell adhesion inhibitors

---

TW496874B|2002-08-01|5-Membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists

---

JP4448134B2|2010-04-07|Cyclic amine BASE-1 inhibitor having a benzamide substituent

---

KR100519201B1|2005-10-06|Melanocortin receptor ligands

---

JP4316238B2|2009-08-19|Acylated piperidine derivatives as melanocortin-4 receptor agonists

---

ES2272703T3|2007-05-01|Piperidine derivatives acilated as receiver agonists of melanocortina-4.

---

KR100661118B1|2006-12-26|Melanocortin receptor agonists

---

DE60205465T2|2006-04-20|Piperazine derivatives as agonists of the melanocortin receptor

---

EP0405537B1|2004-09-08|N-substituted cycloalkyl and polycycloalkyl alpha-substituted Trp-Phe- and phenethylamine derivatives

---

AU2002320494B2|2006-06-29|Bridged piperidine derivatives as melanocortin receptor agonists

---

DE60106422T2|2006-02-09|Dipeptidylpeptidase iv inhibitors

---

RU2351588C2|2009-04-10|N-phenyl|methyl-benzamide derivatives, and their application in therapy

---

DE60219295T2|2008-01-03|Acylated piperidine derivatives than melanocortin-4 receptor agonists

---

US7320960B2|2008-01-22|Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4

---

US7049297B2|2006-05-23|Indazole peptidomimetics as thrombin receptor antagonists

---

EP0792289B1|2000-07-12|Low molecular weight peptidomimetic growth hormone secretagogues

---

KR100639055B1|2006-10-27|Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 and a pharmaceutical composition comprising them

---

US7132539B2|2006-11-07|Melanocortin receptor ligands

---

US5777112A|1998-07-07|Piperazine compounds promote release of growth hormone

---

RU2092491C1|1997-10-10|Peptide derivatives or their pharmaceutically acceptable salts, method of synthesis of peptide derivatives and pharmaceutical composition

---

EP1001974B1|2006-05-24|4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4

---

KR101432112B1|2014-08-21|New Carbonylated |cyclohexanes as dopamine D3 receptor ligands

---

JP2013241447A|2013-12-05|Synthetic peptide amides and dimers thereof

同族专利:

---

公开号 | 公开日

---

JP2005503342A|2005-02-03|

---

PE20021087A1|2003-02-20|

---

MA27016A1|2004-12-20|

---

BR0209193A|2005-10-25|

---

KR20060029706A|2006-04-06|

---

US7087759B2|2006-08-08|

---

AU2002254744B2|2006-02-23|

---

EP1390361A4|2005-10-05|

---

IL157969D0|2004-03-28|

---

EP1390361A2|2004-02-25|

---

RU2277535C2|2006-06-10|

---

WO2002085925A3|2003-12-11|

---

US20030109556A1|2003-06-12|

---

NO20034774L|2003-12-29|

---

HU0500870A2|2005-12-28|

---

HU0500870A3|2008-03-28|

---

US20040224985A1|2004-11-11|

---

CN1543461A|2004-11-03|

---

NZ528262A|2007-04-27|

---

PL373503A1|2005-09-05|

---

US6911447B2|2005-06-28|

---

MXPA03009791A|2004-01-29|

---

SK13222003A3|2004-04-06|

---

ZA200307439B|2004-10-06|

---

CA2444599A1|2002-10-31|

---

AR035863A1|2004-07-21|

---

KR100662309B1|2007-02-28|

---

NO20034774D0|2003-10-24|

---

WO2002085925A2|2002-10-31|

---

CZ20032806A3|2004-02-18|

---

RU2003134019A|2005-06-10|

---

US20060106059A1|2006-05-18|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

法律状态:
2001-04-25|Priority to US28661001P

---

2001-04-25|Priority to US60/286,610

---

2002-04-24|Application filed by 더 프록터 앤드 갬블 캄파니

---

2002-04-24|Priority to PCT/US2002/013340

---

2004-01-24|Publication of KR20040007509A

---

2007-02-28|Application granted

---

2007-02-28|Publication of KR100662309B1

优先权:

---

申请号 | 申请日 | 专利标题

---

US28661001P| true| 2001-04-25|2001-04-25|

---

US60/286,610|2001-04-25|

---

PCT/US2002/013340|WO2002085925A2|2001-04-25|2002-04-24|Melanocortin receptor ligands|